CCNE1 encodes cyclin E1, a regulatory subunit of the cyclin-dependent kinase CDK2. Cyclin E1 binds and activates CDK2, driving phosphorylation of key substrates such as RB1 to promote the G1/S transition of the cell cycle and commitment to S-phase entry. Cyclin E1 itself has no catalytic activity; its role is to confer substrate specificity and temporal activation on CDK2. The protein is predominantly nuclear and its abundance is tightly regulated by SCF-FBXW7-dependent ubiquitin-mediated proteolysis, triggered by phosphodegron motifs phosphorylated by CDK2 and GSK3. CCNE1 amplification and overexpression are frequent in cancers, particularly high-grade serous ovarian cancer (~22% of TCGA cases), where they drive replication stress and genomic instability.
| GO Term | Evidence | Action | Reason |
|---|---|---|---|
|
GO:0000082
G1/S transition of mitotic cell cycle
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: Core function. Cyclin E1 is the canonical regulator of G1/S transition via CDK2 activation. Extensively supported by phylogenetic inference (IBA) and all literature.
Reason: G1/S transition is the defining biological process for cyclin E1. The deep research (CCNE1-deep-research-falcon.md) confirms "Cyclin E1 is a non-enzymatic regulatory subunit whose primary molecular function is to bind and activate CDK2, thereby promoting late G1 progression and G1/S transition" (kasirzadeh2024targetingcdk2to). IBA annotations for such core functions are typically well-reviewed.
Supporting Evidence:
PMID:15838514
Cyclin E-Cdk2 has long been considered an essential and master regulator of progression through G1 phase of the cell cycle
|
|
GO:0005634
nucleus
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: Cyclin E1 is a nuclear protein as established by multiple lines of evidence including the UniProt record which states "Nucleus" with experimental evidence from PMID:7739542.
Reason: Nuclear localization of cyclin E1 is well established. UniProt states "SUBCELLULAR LOCATION: Nucleus" with experimental evidence. IBA annotation is consistent.
Supporting Evidence:
PMID:19942931
Mtd expression in proliferating cells colocalized with cyclin E1, a G(1)/S phase cell cycle regulator
|
|
GO:0005737
cytoplasm
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: Cyclin E1 is also found in the cytoplasm. IHC studies show both nuclear and cytoplasmic localization, and the deep research notes nucleocytoplasmic shuttling.
Reason: Cytoplasmic localization is supported by IHC evidence showing "cytoplasmic cyclin E1 was frequently high (70% high vs 30% low)" in ovarian cancer (lashen2024theclinicopathologicalsignificance). Cyclin E and CDK2 are known to shuttle between nucleus and cytoplasm (chen2025targetingcdk2and). IBA annotation is consistent.
|
|
GO:0016538
cyclin-dependent protein serine/threonine kinase regulator activity
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: Core molecular function of cyclin E1. It is a non-enzymatic regulatory subunit that binds and activates CDK2, a cyclin-dependent serine/threonine kinase.
Reason: This is the defining molecular function of cyclin E1. It does not have kinase activity itself but activates CDK2. PMID:8207080 confirms "Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2." The IBA annotation is at the right level of specificity.
Supporting Evidence:
PMID:8207080
Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2, which is activated shortly before S-phase entry, thus defining it as a G1 cyclin
|
|
GO:0097134
cyclin E1-CDK2 complex
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: Cyclin E1 is a defining component of the cyclin E1-CDK2 complex. Crystal structure of the complex has been solved (PDB:1W98, PMID:15660127).
Reason: UniProt states "Interacts with CDK2 protein kinase to form a serine/threonine kinase holoenzyme complex." Multiple crystal structures confirm this (PDB:1W98). ComplexPortal entry CPX-2015 explicitly defines the Cyclin E1-CDK2 complex.
|
|
GO:0005815
microtubule organizing center
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: Cyclin E-CDK2 is known to play a role in centrosome duplication, and localization to centrosomes (microtubule organizing centers) has been reported in the literature for cyclin E in model organisms. The IBA annotation reflects phylogenetic inference from orthologs.
Reason: Cyclin E-CDK2 activity is required for centrosome duplication, and cyclin E has been shown to localize to centrosomes. This is supported by the broader cell cycle biology literature and is phylogenetically conserved (IBA).
|
|
GO:1900087
positive regulation of G1/S transition of mitotic cell cycle
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: Cyclin E1 positively regulates G1/S transition by activating CDK2, which phosphorylates RB1 to release E2F transcription factors for S-phase gene expression.
Reason: This is a core function. The deep research confirms "CDK2-cyclin E activity promotes S-phase entry in large part by phosphorylating RB, enabling E2F transcriptional activation" (kasirzadeh2024targetingcdk2to). The IBA annotation is at the right level of specificity.
Supporting Evidence:
PMID:15838514
Cyclin E-Cdk2 has long been considered an essential and master regulator of progression through G1 phase of the cell cycle
|
|
GO:0005634
nucleus
|
IEA
GO_REF:0000120 |
ACCEPT |
Summary: IEA annotation for nuclear localization, consistent with the IBA and IDA annotations for the same term.
Reason: Redundant with IBA and IDA annotations but not wrong. Nuclear localization is well established for cyclin E1.
|
|
GO:0051301
cell division
|
IEA
GO_REF:0000043 |
ACCEPT |
Summary: IEA annotation from UniProt keyword mapping. Cell division is a broad term that encompasses the G1/S transition role of cyclin E1.
Reason: While broader than the more specific G1/S transition annotations, this IEA is not wrong. Cyclin E1 is clearly involved in cell division. The UniProt record includes "Cell cycle; Cell division" as keywords.
|
|
GO:0005515
protein binding
|
IPI
PMID:10330164 Specificity of cyclin E-Cdk2, TFIIB, and E1A interactions wi... |
MARK AS OVER ANNOTATED |
Summary: Interaction with p300 coactivator. PMID:10330164 shows cyclin E-Cdk2 binds to the COOH-terminal region of p300, though this is described as a complex interaction (cyclin E-Cdk2 rather than cyclin E alone).
Reason: The term "protein binding" is uninformative. The actual finding is a specific interaction of cyclin E-Cdk2 complex with the p300 coactivator. However, the GO guidelines discourage generic protein binding annotations.
Supporting Evidence:
PMID:10330164
the COOH-terminal region of p300 binds to cyclin E-cyclin-dependent kinase 2 (cyclin E-Cdk2) and TFIIB
|
|
GO:0005515
protein binding
|
IPI
PMID:11533444 Phosphorylation-dependent ubiquitination of cyclin E by the ... |
MARK AS OVER ANNOTATED |
Summary: Interaction with FBXW7 (SCFFbw7) for phosphorylation-dependent ubiquitination. This is a well-characterized substrate-E3 ligase interaction.
Reason: The term "protein binding" is uninformative. The actual interaction is between cyclin E and FBXW7 as part of SCF-mediated ubiquitination. This is better captured by other annotations related to cyclin E degradation.
Supporting Evidence:
PMID:11533444
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase
|
|
GO:0005515
protein binding
|
IPI
PMID:16223725 The loss of PIN1 deregulates cyclin E and sensitizes mouse e... |
MARK AS OVER ANNOTATED |
Summary: Interaction with PIN1 prolyl isomerase. PIN1 regulates cyclin E stability.
Reason: Generic protein binding is uninformative. The actual finding is PIN1 regulation of cyclin E stability.
Supporting Evidence:
PMID:16223725
The loss of PIN1 deregulates cyclin E and sensitizes mouse embryo fibroblasts to genomic instability
|
|
GO:0005515
protein binding
|
IPI
PMID:16431923 The nucleocapsid protein of severe acute respiratory syndrom... |
MARK AS OVER ANNOTATED |
Summary: Interaction with SARS-CoV nucleocapsid protein, which inhibits cyclin-CDK activity. This is a viral pathogen interaction, not a core function.
Reason: Generic protein binding is uninformative. The interaction is with a viral protein (SARS-CoV nucleocapsid) and represents pathogen interference with cell cycle, not a core function of cyclin E1.
Supporting Evidence:
PMID:16431923
The nucleocapsid protein of severe acute respiratory syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks S phase progression in mammalian cells
|
|
GO:0005515
protein binding
|
IPI
PMID:16504183 Regulation of the transcription factor FOXM1c by Cyclin E/CD... |
MARK AS OVER ANNOTATED |
Summary: Interaction with FOXM1c transcription factor, regulated by Cyclin E/CDK2. UniProt lists FOXM1 as an interaction partner.
Reason: Generic protein binding is uninformative. The actual finding is regulation of FOXM1c by cyclin E/CDK2 complex phosphorylation.
Supporting Evidence:
PMID:16504183
Regulation of the transcription factor FOXM1c by Cyclin E/CDK2
|
|
GO:0005515
protein binding
|
IPI
PMID:16721056 G1/S Cyclins interact with regulatory subunit of PKA via A-k... |
MARK AS OVER ANNOTATED |
Summary: Interaction with AKAP95 (A-kinase anchoring protein). G1/S cyclins interact with PKA regulatory subunit via AKAP95.
Reason: Generic protein binding is uninformative. UniProt lists AKAP8 as an interaction partner.
Supporting Evidence:
PMID:16721056
G1/S Cyclins interact with regulatory subunit of PKA via A-kinase anchoring protein, AKAP95
|
|
GO:0005515
protein binding
|
IPI
PMID:16765349 Increased p21 expression and complex formation with cyclin E... |
MARK AS OVER ANNOTATED |
Summary: Interaction with p21 (CDKN1A) in retinoid-induced apoptosis. p21 is a well-known CDK inhibitor that forms complexes with cyclin E/CDK2.
Reason: Generic protein binding is uninformative. The cyclin E-CDK2-p21 interaction is a core regulatory mechanism but should be annotated more specifically. UniProt lists CDKN1A with 11 experiments.
Supporting Evidence:
PMID:16765349
Increased p21 expression and complex formation with cyclin E/CDK2 in retinoid-induced pre-B lymphoma cell apoptosis
|
|
GO:0005515
protein binding
|
IPI
PMID:17254966 Cdk-inhibitory activity and stability of p27Kip1 are directl... |
MARK AS OVER ANNOTATED |
Summary: Interaction with p27Kip1 (CDKN1B). This is a key CDK inhibitor that regulates cyclin E-CDK2 activity.
Reason: Generic protein binding is uninformative. The cyclin E-CDK2-p27 interaction is well characterized. UniProt lists CDKN1B with 12 experiments.
Supporting Evidence:
PMID:17254966
Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases
|
|
GO:0005515
protein binding
|
IPI
PMID:17254967 p27 phosphorylation by Src regulates inhibition of cyclin E-... |
MARK AS OVER ANNOTATED |
Summary: Another study on p27-cyclin E-Cdk2 interaction, showing Src-dependent phosphorylation of p27 regulates inhibition of cyclin E-Cdk2.
Reason: Generic protein binding is uninformative. This is the same well-characterized p27-cyclin E-CDK2 interaction.
Supporting Evidence:
PMID:17254967
p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2
|
|
GO:0005515
protein binding
|
IPI
PMID:17525332 ATM and ATR substrate analysis reveals extensive protein net... |
MARK AS OVER ANNOTATED |
Summary: Large-scale ATM/ATR substrate analysis. This is a high-throughput study identifying proteins in DNA damage response networks, not a focused study on cyclin E function.
Reason: Generic protein binding from a high-throughput study. Does not provide specific information about cyclin E1 function.
Supporting Evidence:
PMID:17525332
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage
|
|
GO:0005515
protein binding
|
IPI
PMID:19470470 RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA ... |
MARK AS OVER ANNOTATED |
Summary: Study on RSK1-p27Kip1 phosphorylation. Cyclin E is mentioned as a binding partner of p27 but the study focuses on RSK1 function.
Reason: Generic protein binding is uninformative. The study focuses on RSK1 regulation of p27, with cyclin E as a known interactor.
Supporting Evidence:
PMID:19470470
RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility
|
|
GO:0005515
protein binding
|
IPI
PMID:21092281 HTLV-I p30 inhibits multiple S phase entry checkpoints, decr... |
MARK AS OVER ANNOTATED |
Summary: HTLV-I p30 decreases cyclin E-CDK2 interactions. This is a viral interference study.
Reason: Generic protein binding is uninformative. This describes viral pathogen interference with cyclin E-CDK2, not a core function.
Supporting Evidence:
PMID:21092281
HTLV-I p30 inhibits multiple S phase entry checkpoints, decreases cyclin E-CDK2 interactions and delays cell cycle progression
|
|
GO:0005515
protein binding
|
IPI
PMID:21952639 NIRF constitutes a nodal point in the cell cycle network and... |
MARK AS OVER ANNOTATED |
Summary: Interaction with UHRF2 (NIRF), which ubiquitinates cyclin E1. UniProt confirms this interaction with 4 experiments.
Reason: Generic protein binding is uninformative. The actual interaction is a substrate-E3 ligase relationship where UHRF2 ubiquitinates cyclin E1. UniProt states "Interacts directly with UHRF2; the interaction ubiquitinates CCNE1."
Supporting Evidence:
PMID:21952639
the ubiquitin ligase NIRF (also known as UHRF2), which induces G1 arrest, interacts with multiple cell cycle proteins including cyclins (A2, B1, D1 and E1), p53 and pRB, and ubiquitinates cyclins D1 and E1
|
|
GO:0005515
protein binding
|
IPI
PMID:21988832 Toward an understanding of the protein interaction network o... |
MARK AS OVER ANNOTATED |
Summary: High-throughput protein interaction study of the human liver. Not a focused study on cyclin E1 function.
Reason: Generic protein binding from a large-scale interactome study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:21988832
Toward an understanding of the protein interaction network of the human liver
|
|
GO:0005515
protein binding
|
IPI
PMID:23455922 Interlaboratory reproducibility of large-scale human protein... |
MARK AS OVER ANNOTATED |
Summary: Large-scale AP-MS reproducibility study. Not a focused study on cyclin E1.
Reason: Generic protein binding from a high-throughput methods study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:23455922
Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS
|
|
GO:0005515
protein binding
|
IPI
PMID:23602568 The protein interaction landscape of the human CMGC kinase g... |
MARK AS OVER ANNOTATED |
Summary: CMGC kinase group interactome study. CDK2 is a CMGC kinase, so cyclin E1 would be identified as an interactor.
Reason: Generic protein binding from a kinase interactome study. The cyclin E-CDK2 interaction is already well captured by more specific annotations.
Supporting Evidence:
PMID:23602568
The protein interaction landscape of the human CMGC kinase group
|
|
GO:0005515
protein binding
|
IPI
PMID:23853094 Foxp3 protein stability is regulated by cyclin-dependent kin... |
MARK AS OVER ANNOTATED |
Summary: Foxp3 stability regulation by CDK2. The study shows CDK2 phosphorylates Foxp3, with cyclin E as the activating partner.
Reason: Generic protein binding is uninformative. The actual biology is CDK2 phosphorylation of Foxp3, where cyclin E1 is the activating cyclin partner.
Supporting Evidence:
PMID:23853094
Foxp3 protein stability is regulated by cyclin-dependent kinase 2
|
|
GO:0005515
protein binding
|
IPI
PMID:24358021 Polycomb protein SCML2 regulates the cell cycle by binding a... |
MARK AS OVER ANNOTATED |
Summary: SCML2 binding to CDK/CYCLIN/p21 complexes. Cyclin E is one of the cyclins in such complexes.
Reason: Generic protein binding is uninformative. The study describes SCML2 modulating CDK/cyclin/p21 complexes, with cyclin E as one component.
Supporting Evidence:
PMID:24358021
Polycomb protein SCML2 regulates the cell cycle by binding and modulating CDK/CYCLIN/p21 complexes
|
|
GO:0005515
protein binding
|
IPI
PMID:25241761 Using an in situ proximity ligation assay to systematically ... |
MARK AS OVER ANNOTATED |
Summary: In situ proximity ligation assay (PLA) study for profiling endogenous protein-protein interactions.
Reason: Generic protein binding from a methods-focused study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:25241761
Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network
|
|
GO:0005515
protein binding
|
IPI
PMID:25852190 Integrative analysis of kinase networks in TRAIL-induced apo... |
MARK AS OVER ANNOTATED |
Summary: Kinase network analysis in TRAIL-induced apoptosis. High-throughput study.
Reason: Generic protein binding from a high-throughput network analysis study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:25852190
Integrative analysis of kinase networks in TRAIL-induced apoptosis provides a source of potential targets for combination therapy
|
|
GO:0005515
protein binding
|
IPI
PMID:28514442 Architecture of the human interactome defines protein commun... |
MARK AS OVER ANNOTATED |
Summary: Large-scale human interactome architecture study.
Reason: Generic protein binding from a large-scale interactome study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:28514442
Architecture of the human interactome defines protein communities and disease networks
|
|
GO:0005515
protein binding
|
IPI
PMID:32296183 A reference map of the human binary protein interactome. |
MARK AS OVER ANNOTATED |
Summary: Binary protein interactome reference map.
Reason: Generic protein binding from a large-scale interactome mapping study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:32296183
A reference map of the human binary protein interactome
|
|
GO:0005515
protein binding
|
IPI
PMID:33961781 Dual proteome-scale networks reveal cell-specific remodeling... |
MARK AS OVER ANNOTATED |
Summary: Dual proteome-scale interactome study showing cell-specific remodeling.
Reason: Generic protein binding from a large-scale interactome study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:33961781
Dual proteome-scale networks reveal cell-specific remodeling of the human interactome
|
|
GO:0005515
protein binding
|
IPI
PMID:34591612 A protein interaction landscape of breast cancer. |
MARK AS OVER ANNOTATED |
Summary: Protein interaction landscape of breast cancer.
Reason: Generic protein binding from a tissue-specific interactome study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:34591612
A protein interaction landscape of breast cancer
|
|
GO:0005515
protein binding
|
IPI
PMID:35271311 OpenCell: Endogenous tagging for the cartography of human ce... |
MARK AS OVER ANNOTATED |
Summary: OpenCell endogenous tagging and cartography study.
Reason: Generic protein binding from a large-scale cellular organization study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:35271311
OpenCell: Endogenous tagging for the cartography of human cellular organization
|
|
GO:0005515
protein binding
|
IPI
PMID:35512704 Systematic discovery of mutation-directed neo-protein-protei... |
MARK AS OVER ANNOTATED |
Summary: Mutation-directed neo-protein-protein interactions in cancer.
Reason: Generic protein binding from a high-throughput cancer study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:35512704
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer
|
|
GO:0005515
protein binding
|
IPI
PMID:40205054 Multimodal cell maps as a foundation for structural and func... |
MARK AS OVER ANNOTATED |
Summary: Multimodal cell maps study.
Reason: Generic protein binding from a large-scale cellular mapping study. Uninformative for cyclin E1 functional annotation.
Supporting Evidence:
PMID:40205054
Multimodal cell maps as a foundation for structural and functional genomics
|
|
GO:0005515
protein binding
|
IPI
PMID:8553588 Human papillomavirus E7 oncoproteins bind a single form of c... |
MARK AS OVER ANNOTATED |
Summary: HPV E7 oncoproteins bind cyclin E in a complex with CDK2 and p107. This represents viral oncogene interaction with the cyclin E-CDK2 complex.
Reason: Generic protein binding is uninformative. The actual finding involves viral E7 oncoprotein binding to cyclin E-CDK2-p107 complexes, which is a pathogen interaction, not a core function.
Supporting Evidence:
PMID:8553588
Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107
|
|
GO:0005515
protein binding
|
IPI
PMID:8756624 Cyclin-binding motifs are essential for the function of p21C... |
MARK AS OVER ANNOTATED |
Summary: Cyclin-binding motifs essential for p21CIP1 function. This demonstrates the p21-cyclin E interaction is functionally important.
Reason: Generic protein binding is uninformative. The study reveals specific cyclin-binding motifs in p21, but the annotation should be more specific than "protein binding."
Supporting Evidence:
PMID:8756624
Cyclin-binding motifs are essential for the function of p21CIP1
|
|
GO:0005515
protein binding
|
IPI
PMID:9840943 Cyclin E2, a novel human G1 cyclin and activating partner of... |
MARK AS OVER ANNOTATED |
Summary: Cyclin E2 discovery paper that also characterizes cyclin E1 interactions with CDK2 and CDK3.
Reason: Generic protein binding is uninformative. The CDK2 interaction is already captured by the more specific cyclin E1-CDK2 complex annotation (GO:0097134).
Supporting Evidence:
PMID:9840943
Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins
|
|
GO:0000307
cyclin-dependent protein kinase holoenzyme complex
|
IEA
GO_REF:0000107 |
ACCEPT |
Summary: IEA annotation for CDK holoenzyme complex membership. This is a more general parent of cyclin E1-CDK2 complex (GO:0097134).
Reason: While more general than GO:0097134 (cyclin E1-CDK2 complex), this IEA annotation is not wrong. Cyclin E1 is indeed a component of a cyclin-dependent protein kinase holoenzyme complex (the CDK2 holoenzyme). It is acceptable for IEA annotations to be broader.
|
|
GO:0016301
kinase activity
|
IEA
GO_REF:0000107 |
REMOVE |
Summary: IEA annotation attributing kinase activity to cyclin E1. However, cyclin E1 is NOT a kinase; it is a regulatory subunit that activates CDK2.
Reason: Cyclin E1 does not have kinase activity itself. It is a non-enzymatic regulatory subunit that binds and activates CDK2. PMID:8207080 confirms "Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2." The kinase activity belongs to CDK2, not cyclin E1. The correct MF annotation is GO:0016538 (cyclin-dependent protein serine/threonine kinase regulator activity), which is already annotated. This IEA annotation is incorrect and should be removed.
Supporting Evidence:
PMID:8207080
Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2, which is activated shortly before S-phase entry
|
|
GO:0016538
cyclin-dependent protein serine/threonine kinase regulator activity
|
IEA
GO_REF:0000107 |
ACCEPT |
Summary: IEA annotation consistent with the IBA annotation for the same term. This is the correct molecular function for cyclin E1.
Reason: Consistent with the IBA annotation. This is the defining molecular function of cyclin E1 as a CDK2 regulatory subunit.
|
|
GO:0019901
protein kinase binding
|
IEA
GO_REF:0000107 |
ACCEPT |
Summary: IEA annotation for protein kinase binding. Cyclin E1 does bind CDK2 (a protein kinase), so this is technically correct but vague.
Reason: Cyclin E1 binds CDK2, which is a protein kinase. UniProt states "Interacts with CDK2 protein kinase to form a serine/threonine kinase holoenzyme complex" (PMID:15660127). While more informative terms exist (GO:0016538), this IEA annotation is not incorrect and can be retained as a broader term.
|
|
GO:0097134
cyclin E1-CDK2 complex
|
IEA
GO_REF:0000107 |
ACCEPT |
Summary: IEA annotation consistent with IBA annotation for the same term.
Reason: Consistent with the IBA annotation. Cyclin E1 is a defining component of the cyclin E1-CDK2 complex (ComplexPortal CPX-2015).
|
|
GO:0005654
nucleoplasm
|
IDA
GO_REF:0000052 |
ACCEPT |
Summary: IDA annotation from HPA immunofluorescence data showing nucleoplasmic localization.
Reason: Nucleoplasmic localization is consistent with cyclin E1 being a nuclear protein that functions in cell cycle regulation within the nucleus. This is supported by multiple lines of evidence.
|
|
GO:0000082
G1/S transition of mitotic cell cycle
|
NAS
PMID:15838514 Cyclin E in normal and neoplastic cell cycles. |
ACCEPT |
Summary: NAS annotation from a review article on cyclin E in normal and neoplastic cell cycles. Confirms the core function of cyclin E1 in G1/S transition.
Reason: Core function annotation supported by review literature. PMID:15838514 states "Cyclin E-Cdk2 has long been considered an essential and master regulator of progression through G1 phase of the cell cycle."
Supporting Evidence:
PMID:15838514
Cyclin E-Cdk2 has long been considered an essential and master regulator of progression through G1 phase of the cell cycle
|
|
GO:0000082
G1/S transition of mitotic cell cycle
|
IMP
PMID:23083510 miR-16 inhibits the proliferation and angiogenesis-regulatin... |
ACCEPT |
Summary: IMP annotation from a study showing miR-16 targets cyclin E1 to inhibit mesenchymal stem cell proliferation and induce cell cycle arrest. Cyclin E1 knockdown/downregulation caused cell cycle arrest, supporting its role in G1/S transition.
Reason: The study shows that miR-16 targets cyclin E1, and over-expression of miR-16 "inhibited the proliferation and migration of decidua-derived mesenchymal stem cells and induced cell-cycle arrest by targeting cyclin E1" (PMID:23083510). This supports cyclin E1 involvement in G1/S transition.
Supporting Evidence:
PMID:23083510
over-expressed miR-16 inhibited the proliferation and migration of decidua-derived mesenchymal stem cells and induced cell-cycle arrest by targeting cyclin E1
|
|
GO:1902462
positive regulation of mesenchymal stem cell proliferation
|
IMP
PMID:23083510 miR-16 inhibits the proliferation and angiogenesis-regulatin... |
KEEP AS NON CORE |
Summary: IMP annotation from miR-16 study in pre-eclampsia. While cyclin E1 promotes proliferation of mesenchymal stem cells (shown by miR-16 targeting), this is a very specific biological context (decidual MSCs in pre-eclampsia) rather than a core function.
Reason: Cyclin E1 does promote proliferation in MSCs as shown by the miR-16 study, but this is a pleiotropic effect of its general cell cycle role in a specific cell type context, not a core evolved function. The annotation is technically supported but represents a context-specific manifestation.
Supporting Evidence:
PMID:23083510
over-expressed miR-16 inhibited the proliferation and migration of decidua-derived mesenchymal stem cells and induced cell-cycle arrest by targeting cyclin E1
|
|
GO:0000082
G1/S transition of mitotic cell cycle
|
IMP
PMID:25732226 MicroRNA-30c-2-3p negatively regulates NF-ÎșB signaling and c... |
ACCEPT |
Summary: IMP annotation from study showing miR-30c-2-3p targets CCNE1 in breast cancer cells. Inhibition of CCNE1 phenocopied effects on cell proliferation.
Reason: The study confirms that CCNE1 downregulation affects cell cycle progression. "inhibition of CCNE1 phenocopied the effects on cell proliferation" (PMID:25732226). Supports G1/S transition role.
Supporting Evidence:
PMID:25732226
inhibition of CCNE1 phenocopied the effects on cell proliferation
|
|
GO:0005515
protein binding
|
IPI
PMID:21540187 Inhibitor of cyclin-dependent kinase (CDK) interacting with ... |
MARK AS OVER ANNOTATED |
Summary: Interaction with INCA1 (inhibitor of CDK interacting with cyclin A1). UniProt confirms "Interacts with INCA1" (PMID:21540187).
Reason: Generic protein binding is uninformative. The actual interaction is between cyclin E1 and INCA1, a CDK inhibitor. UniProt confirms this interaction.
Supporting Evidence:
PMID:21540187
we identified INCA1 as an interaction partner and a substrate of cyclin A1 in complex with CDK2
|
|
GO:0005634
nucleus
|
IDA
PMID:19942931 Mtd/Bok takes a swing: proapoptotic Mtd/Bok regulates tropho... |
ACCEPT |
Summary: Nuclear localization of cyclin E1 observed in trophoblast cells. The study shows Mtd-L colocalizes with cyclin E1 in the nuclear compartment.
Reason: Nuclear localization confirmed by immunofluorescence in proliferating trophoblast cells. "Mtd expression in proliferating cells colocalized with cyclin E1, a G(1)/S phase cell cycle regulator" (PMID:19942931). Consistent with UniProt annotation.
Supporting Evidence:
PMID:19942931
Mtd expression in proliferating cells colocalized with cyclin E1, a G(1)/S phase cell cycle regulator
|
|
GO:0005515
protein binding
|
IPI
PMID:17434132 Structure of a Fbw7-Skp1-cyclin E complex: multisite-phospho... |
MARK AS OVER ANNOTATED |
Summary: Structural study of Fbw7-Skp1-cyclin E complex. Demonstrates the molecular basis for cyclin E recognition by SCF-FBXW7 for ubiquitin-mediated degradation. This is a well-characterized interaction.
Reason: Generic protein binding is uninformative. The actual finding is the structural basis for FBXW7 recognition of phosphorylated cyclin E degrons. This interaction is critical for cyclin E turnover but "protein binding" does not capture the functional significance.
Supporting Evidence:
PMID:17434132
Cyclin E degradation is triggered by multisite phosphorylation, which induces binding to the SCF(Fbw7) ubiquitin ligase complex
|
|
GO:0005654
nucleoplasm
|
TAS
Reactome:R-HSA-187520 |
ACCEPT |
Summary: Reactome TAS annotation for nucleoplasmic localization, from the Cyclin E/A:Cdk2-mediated phosphorylation of p27/p21 reaction.
Reason: Cyclin E-CDK2 mediates phosphorylation of p27/p21 in the nucleoplasm as part of the Skp2-mediated degradation pathway. Consistent with nuclear function.
|
|
GO:0005654
nucleoplasm
|
TAS
Reactome:R-HSA-187552 |
ACCEPT |
Summary: Reactome TAS annotation for nucleoplasm, from binding of phospho-p27/p21 to SCF(Skp2):Cks1 complex.
Reason: Consistent with established nucleoplasmic function of cyclin E-CDK2 complex.
|
|
GO:0005654
nucleoplasm
|
TAS
Reactome:R-HSA-187574 |
ACCEPT |
Summary: Reactome TAS annotation for nucleoplasm, from degradation of ubiquitinated p27/p21 by 26S proteasome.
Reason: Consistent with nucleoplasmic localization during cell cycle regulation.
|
|
GO:0005654
nucleoplasm
|
TAS
Reactome:R-HSA-187575 |
ACCEPT |
Summary: Reactome TAS annotation for nucleoplasm, from ubiquitination of phospho-p27/p21.
Reason: Consistent with nucleoplasmic localization during cell cycle regulation.
|
|
GO:0005654
nucleoplasm
|
TAS
Reactome:R-HSA-188350 |
ACCEPT |
Summary: Reactome TAS annotation for nucleoplasm, from CAK-mediated phosphorylation of Cyclin E:Cdk2.
Reason: Consistent with nucleoplasmic localization during cell cycle regulation.
|
|
GO:0005654
nucleoplasm
|
TAS
Reactome:R-HSA-188386 |
ACCEPT |
Summary: Reactome TAS annotation for nucleoplasm, from association of Rb with Cyclin E:Cdk2 complexes.
Reason: Consistent with nucleoplasmic localization for RB1 phosphorylation by cyclin E-CDK2.
|
|
GO:0005654
nucleoplasm
|
TAS
Reactome:R-HSA-188390 |
ACCEPT |
Summary: Reactome TAS annotation for nucleoplasm, from Cyclin E:CDK2-mediated phosphorylation of RB1.
Reason: Consistent with nucleoplasmic localization for the core function of RB1 phosphorylation.
|
|
GO:0005654
nucleoplasm
|
TAS
Reactome:R-HSA-69005 |
ACCEPT |
Summary: Reactome TAS annotation for nucleoplasm, from Cdc6 phosphorylation by CDK.
Reason: Consistent with nucleoplasmic localization. Cdc6 phosphorylation by cyclin E-CDK2 is part of DNA replication licensing.
|
|
GO:0005654
nucleoplasm
|
TAS
Reactome:R-HSA-69195 |
ACCEPT |
Summary: Reactome TAS annotation for nucleoplasm, from phosphorylation of Cyclin E:CDK2 complexes by WEE1.
Reason: Consistent with nucleoplasmic localization during cell cycle checkpoint regulation.
|
|
GO:0005654
nucleoplasm
|
TAS
Reactome:R-HSA-69199 |
ACCEPT |
Summary: Reactome TAS annotation for nucleoplasm, from dephosphorylation of Cyclin E:Cdk2 complexes by Cdc25A.
Reason: Consistent with nucleoplasmic localization during cell cycle regulation.
|
|
GO:0005829
cytosol
|
TAS
Reactome:R-HSA-157906 |
ACCEPT |
Summary: Reactome TAS annotation for cytosol, from translocation of Cyclin E:Cdk2 complex to the nucleus. Cyclin E-CDK2 is present in the cytosol before nuclear translocation.
Reason: Cyclin E-CDK2 complexes form in the cytosol before translocation to the nucleus. The Reactome reaction R-HSA-157906 specifically describes this translocation, implying cytosolic presence.
|
|
GO:0005829
cytosol
|
TAS
Reactome:R-HSA-69191 |
ACCEPT |
Summary: Reactome TAS annotation for cytosol, from formation of Cyclin E:Cdk2 complexes.
Reason: Cyclin E-CDK2 complex formation occurs in the cytosol. Consistent with known biology of cyclin-CDK complex assembly.
|
|
GO:0005829
cytosol
|
TAS
Reactome:R-HSA-8961846 |
ACCEPT |
Summary: Reactome TAS annotation for cytosol, from CCNE1 gene transcription stimulated by E2F1. This annotation seems to be about the gene product being present in cytosol in the context of its transcriptional regulation.
Reason: While the Reactome reaction is about transcriptional regulation, cyclin E1 protein is synthesized in the cytosol. Consistent with cytoplasmic localization evidence.
|
|
GO:0005829
cytosol
|
TAS
Reactome:R-HSA-9706390 |
ACCEPT |
Summary: Reactome TAS annotation for cytosol from RHOBTB3 interaction at trans-Golgi network. This is a less well-characterized interaction.
Reason: While the RHOBTB3 interaction context is less well characterized for cyclin E1, cytosolic presence is consistent with known nucleocytoplasmic shuttling of cyclin E.
|
|
GO:0006468
protein phosphorylation
|
IMP
PMID:10500095 Cullin-3 targets cyclin E for ubiquitination and controls S ... |
MODIFY |
Summary: PMID:10500095 describes Cullin-3 targeting cyclin E for ubiquitination. The paper discusses cyclin E phosphorylation as a signal for degradation, and cyclin E-CDK2 complex kinase activity, but cyclin E itself does not catalyze phosphorylation. Cyclin E1 is a regulatory subunit, not a kinase.
Reason: Cyclin E1 does not catalyze protein phosphorylation itself. It is a non-enzymatic regulatory subunit that activates CDK2. The annotation should be modified to reflect that cyclin E1 regulates protein kinase activity rather than directly performing phosphorylation. PMID:10500095 discusses "cyclin E-Cdk2 complexes" where CDK2 is the catalytic subunit. The paper actually focuses on "Cyclin E is an unstable protein that is degraded in a ubiquitin- and proteasome-dependent pathway."
Proposed replacements:
regulation of protein kinase activity
Supporting Evidence:
PMID:10500095
Cyclin E is an unstable protein that is degraded in a ubiquitin- and proteasome- dependent pathway
|
|
GO:0005634
nucleus
|
IDA
PMID:16109376 The bromodomain protein Brd4 is a positive regulatory compon... |
ACCEPT |
Summary: PMID:16109376 is about the bromodomain protein Brd4 and P-TEFb, not directly about cyclin E1. Brd4 interacts with cyclinT1 and Cdk9. The reference appears questionable for a CCNE1 nuclear localization annotation, as the paper primarily concerns cyclinT1/Cdk9. However, nuclear localization of cyclin E1 is well established by multiple other lines of evidence, including UniProt annotation with PMID:7739542 and IDA from PMID:19942931.
Reason: Although the specific reference PMID:16109376 may be a curatorial error (the paper focuses on Brd4/P-TEFb/cyclinT1/Cdk9 rather than cyclin E1), the nuclear localization of CCNE1 itself is unambiguously established. UniProt states "SUBCELLULAR LOCATION: Nucleus" with experimental evidence, and multiple other IDA annotations confirm nuclear localization (PMID:19942931). The annotation conclusion is correct even if the cited reference is questionable.
Supporting Evidence:
PMID:16109376
Proteomic analysis revealed that Brd4 interacts with cyclinT1 and Cdk9 that constitutes core positive transcription elongation factor b (P-TEFb)
|
|
GO:0005515
protein binding
|
IPI
PMID:9891079 Cyclin E associates with BAF155 and BRG1, components of the ... |
MARK AS OVER ANNOTATED |
Summary: Interaction with BAF155 and BRG1, components of the SWI-SNF chromatin remodeling complex. Cyclin E associates with these components and modulates BRG1-induced growth arrest.
Reason: Generic protein binding is uninformative. The actual finding is a specific interaction between cyclin E and SWI-SNF complex components (BAF155, BRG1) that may modulate chromatin remodeling during cell cycle progression.
Supporting Evidence:
PMID:9891079
BRG1 and BAF155, mammalian homologs of yeast SWI2 and SWI3, respectively, are found in cyclin E complexes and are phosphorylated by cyclin E-associated kinase activity
|
|
GO:0000082
G1/S transition of mitotic cell cycle
|
NAS
PMID:8207080 Alternative splicing of human cyclin E. |
ACCEPT |
Summary: NAS annotation from the alternative splicing paper. The paper establishes cyclin E as a G1 cyclin that activates CDK2 for S-phase entry.
Reason: PMID:8207080 confirms "Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2, which is activated shortly before S-phase entry, thus defining it as a G1 cyclin." Core function annotation.
Supporting Evidence:
PMID:8207080
Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2, which is activated shortly before S-phase entry, thus defining it as a G1 cyclin
|
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-03-06T03:10:18.530953'
end_time: '2026-03-06T03:23:48.672523'
duration_seconds: 810.14
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: CCNE1
gene_symbol: CCNE1
uniprot_accession: P24864
protein_description: 'RecName: Full=G1/S-specific cyclin-E1;'
gene_info: Name=CCNE1; Synonyms=CCNE;
organism_full: Homo sapiens (Human).
protein_family: Belongs to the cyclin family. Cyclin E subfamily.
protein_domains: Cyclin. (IPR039361); Cyclin-like_dom. (IPR013763); Cyclin-like_sf.
(IPR036915); Cyclin_C-dom. (IPR004367); Cyclin_N. (IPR006671)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
temperature: 0.1
citation_count: 23
BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.
DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'CCNE1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information
Please provide a comprehensive research report on the gene CCNE1 (gene ID: CCNE1, UniProt: P24864) in human.
The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.
BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.
DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'CCNE1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information
Please provide a comprehensive research report on the gene CCNE1 (gene ID: CCNE1, UniProt: P24864) in human.
The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The literature set analyzed corresponds to human CCNE1 (cyclin E1), consistent with UniProt accession P24864. In particular, Zhang et al. studied the full-length human CCNE1 gene product in the context of the cyclin E1:CDK2 complex and mapped a cryptic allosteric pocket at the CCNE1:CDK2 interface near CCNE1 residue N112, confirming that âCCNE1â in these sources refers to the canonical human cyclin E1 protein (zhang2025anallostericcyclin pages 1-3).
Cyclin E1 is a non-enzymatic regulatory subunit (cyclin) whose primary molecular function is to bind and activate CDK2, thereby promoting late G1 progression and G1/S transition. Mechanistically, CDK2âcyclin E activity promotes S-phase entry in large part by phosphorylating RB, enabling E2F transcriptional activation of S-phase genes (kasirzadeh2024targetingcdk2to pages 2-3, lashen2024theclinicopathologicalsignificance pages 1-2).
This RBâE2F placement is also captured in ovarian cancer pathway analyses: cyclin DâCDK4/6 initiates RB phosphorylation in early G1, E2F induces CCNE1 expression, and then cyclin E1âCDK2 further phosphorylates RB to complete E2F activation and commit cells to S phase (lashen2024theclinicopathologicalsignificance pages 1-2).
A central modern concept in CCNE1 biology is that CCNE1 amplification or cyclin E1 overexpression can accelerate G1/S progression, promoting replication stress (RS) and genomic instability; these properties create dependencies on cell-cycle checkpoints and the replication-stress response that can be therapeutically exploited (kim2025cycline1cdk2activation pages 13-14, kim2025cycline1cdk2activation pages 12-13).
In a large epithelial ovarian cancer IHC study, cyclin E1 showed both nuclear and cytoplasmic localization (H-score compartment scoring). High nuclear cyclin E1 expression was associated with shorter progression-free survival (PFS) and overall survival (OS), and cyclin E1 was reported as an independent predictor of poor PFS in multivariable analysis (lashen2024theclinicopathologicalsignificance pages 7-9, lashen2024theclinicopathologicalsignificance pages 11-12).
In the same cohort, cytoplasmic cyclin E1 was frequently high (reported as 70% high vs 30% low among n=260 evaluable patients for that variable) and was also associated with worse survival metrics in analyses reported in the excerpt (lashen2024theclinicopathologicalsignificance pages 7-9).
A recent expert review notes that cyclin E (and cyclin A), together with their associated CDKs, shuttle between nucleus and cytoplasm, implying regulation at the level of nuclear import/export can modulate the functions of cyclin/CDK complexes across compartments (chen2025targetingcdk2and pages 1-3).
Cyclin E1 levels are tightly regulated by ubiquitin-dependent degradation. FBXW7 is an F-box substrate-recognition factor for SCF (Skp1âCullin1âF-box) E3 ubiquitin ligases that recognizes phosphodegron (Cdc4 phosphodegron) motifs, enabling proteasome-mediated turnover of substrates (boretto2024epidermalgrowthfactor pages 1-2).
Direct experimental evidence in engineered human colon organoids shows that FBXW7 mutations increase cyclin E1 (CCNE1) protein levels: âProtein levels of CCNE1⊠were up-regulated in organoids carrying common missense or nonsense mutationsâ (boretto2024epidermalgrowthfactor pages 2-3). A 2024 molecular oncology study further contextualizes CCNE1 as a canonical FBXW7 substrate and cites classic foundational work establishing that cyclin E degradation by SCFâFBXW7 is phosphorylation-dependent (phosphodegron-dependent ubiquitination) (baxter2024cancerâassociatedfbxw7loss pages 15-16).
A recent chemical biology advance mapped a ligandable, cryptic allosteric pocket at the CCNE1:CDK2 interface using covalent probes and crystallography, providing a potential route to modulate cyclin E1âCDK2 function through non-ATP-site mechanisms (zhang2025anallostericcyclin pages 1-3).
A 2024 ovarian cancer cohort/bioinformatics analysis reported CCNE1 amplification in 22% (67/311) of tumors in the TCGA Firehose Legacy ovarian serous cystadenocarcinoma cohort, and showed copy-number correlates with CCNE1 mRNA (Pearson r=0.53, p<0.001) (lashen2024theclinicopathologicalsignificance pages 9-11). This supports CCNE1 amplification as a frequent and clinically relevant molecular subtype in ovarian cancer.
A 2024 expert review focusing on CDK2 highlights that cyclin E upregulation (including CCNE1/CCNE2 amplifications) is associated with poor prognosis and resistance across multiple therapy classes (targeted therapy, immunotherapy, endocrine therapy, chemo/radiotherapy), reinforcing CCNE1 as a practical stratification biomarker for cell-cycle/replication-stressâtargeting strategies (kasirzadeh2024targetingcdk2to pages 1-2).
A 2025 mechanistic/clinical study supports the model that Cyclin E1/CDK2 activation defines vulnerability to WEE1 inhibition, because CCNE1-high tumors have higher baseline replication stress and rely on checkpoint control; WEE1 inhibition exacerbates replication stress and can precipitate cell death (kim2025cycline1cdk2activation pages 12-13).
Recent clinical translational work notes that CCNE1 amplification is routinely reported on most next-generation sequencing platforms, and cyclin E1 IHC can serve as a feasible clinical assay to enrich for Cyclin E1/CDK2-activated tumors (kim2025cycline1cdk2activation pages 13-14).
(A) WEE1 inhibitors (clinical activity examples; biomarker-enriched):
In azenosertib clinical experience summarized in NPJ Precision Oncology, three representative responders with Cyclin E1/CDK2 activation showed week-12 tumor reductions of â57%, â42%, and â30%, including two CCNE1-amplified cases (copy numbers CN=16 and CN=17) and one CCNE1 non-amplified but Cyclin E1-high case (kim2025cycline1cdk2activation pages 12-13). A pharmacodynamic implementation detail used was â„50% reduction in pCDK1(Y15) as a target engagement metric (kim2025cycline1cdk2activation pages 12-13).
(B) Selective CDK2 inhibitors (BLU-222; biomarker-guided development):
Preclinical and translational work on the CDK2 inhibitor BLU-222 proposes CCNE1-high tumors as CDK2-dependent and identifies combinatorial biomarker refinements involving Rb/p16 to enrich for CDK2-inhibitor sensitivity; the work cites the Phase I/II trial VELA (NCT05252416) (house2025profilingtheactivity pages 12-12).
(C) CDK2âcyclin E co-degradation (next-generation modality):
Heterobifunctional degraders that co-degrade CDK2 and cyclin E1 showed substantially stronger antiproliferative potency in CCNE1-amplified cell lines (e.g., low-nM IC50s) compared with a CCNE1-nonamplified line (micromolar-range), and were designed to improve selectivity challenges inherent to ATP-site CDK inhibition (kwiatkowski2025cdk2heterobifunctionaldegraders pages 1-1).
| Topic | Key Point | Quantitative/Statistical Detail | Evidence Type | Source | URL | Citation ID |
|---|---|---|---|---|---|---|
| Core Function & Pathway | CCNE1 activates CDK2 to drive G1/S transition and S-phase entry; amplification causes replication stress and genomic instability. | N/A | Review / Primary | Kim et al. 2025 NPJ Precis Oncol; Kasirzadeh et al. 2024 Future Oncol | Link | (kim2025cycline1cdk2activation pages 13-14, kasirzadeh2024targetingcdk2to pages 1-2) |
| Regulation (Proteolysis) | Regulated by ubiquitin-mediated proteolysis via SCF-FBXW7 E3 ligase recognizing phosphodegrons; FBXW7 loss leads to accumulation. | FBXW7 loss/mutation correlates with CCNE1 protein accumulation in human colon organoids. | Primary Mech. | Boretto et al. 2024 PNAS; Baxter et al. 2024 Mol Oncol | Link | (boretto2024epidermalgrowthfactor pages 2-3, baxter2024cancerâassociatedfbxw7loss pages 15-16) |
| Subcellular Localization | Nuclear accumulation of Cyclin E1 (with CDK2) is a specific prognostic marker in ovarian cancer. | High nuclear CCNE1/CDK2 linked to poor PFS (p=0.018) and OS (p=0.012). | Clinical Cohort | Lashen et al. 2024 Int J Mol Sci | Link | (lashen2024theclinicopathologicalsignificance pages 9-11) |
| Biomarker Statistics | CCNE1 amplification frequency in high-grade serous ovarian cancer (HGSOC). | 22% (67/311) of tumors in TCGA Firehose Legacy ovarian cohort. | Clinical / Bioinf. | Lashen et al. 2024 Int J Mol Sci | Link | (lashen2024theclinicopathologicalsignificance pages 9-11) |
| Therapeutics: WEE1i | CCNE1-high tumors show vulnerability to WEE1 inhibition (azenosertib) due to high baseline replication stress. | Monotherapy partial responses observed: -57%, -42%, -30% tumor reduction (waterfall plot data). | Clinical Phase I | Kim et al. 2025 NPJ Precis Oncol | Link | (kim2025cycline1cdk2activation pages 13-14, kim2025cycline1cdk2activation pages 12-13) |
| Therapeutics: CDK2i | Selective CDK2 inhibitor BLU-222 targets CCNE1-aberrant tumors; Rb/p16 status may refine selection. | VELA Trial (NCT05252416); CDK2i induces G1 arrest or S-phase slippage/collapse. | Preclinical / Phase I | House et al. 2025 Cancer Res | Link | (house2025profilingtheactivity pages 12-12) |
| Therapeutics: Degraders | Heterobifunctional degraders co-degrade CDK2 and Cyclin E1, overcoming kinase homology selectivity issues. | IC50 ~7-16 nM in CCNE1-amp lines vs ~4000 nM in non-amp; >1250-fold CDK1 sparing. | Preclinical | Kwiatkowski et al. 2025 Cell Chem Biol | Link | (kwiatkowski2025cdk2heterobifunctionaldegraders pages 1-1) |
Table: Summary of key findings regarding CCNE1 function, regulation, and clinical targeting from 2024-2025 literature.
Key quantitative points from the retrieved evidence include:
- CCNE1 amplification frequency in TCGA ovarian cohort: 22% (67/311) (lashen2024theclinicopathologicalsignificance pages 9-11).
- Ovarian cancer IHC localization frequency: cytoplasmic cyclin E1 reported as 70% high vs 30% low among n=260 in one analysis subset (lashen2024theclinicopathologicalsignificance pages 7-9).
- Azenosertib clinical response examples in Cyclin E1/CDK2-activated tumors: â57%, â42%, â30% tumor reductions at week 12, with accompanying CCNE1 copy-number and Cyclin E1 H-score annotations (kim2025cycline1cdk2activation pages 12-13).
- Adavosertib (AZD1775) CCNE1-amplified basket trial design: Phase 2 (NCT03253679) enrolled 31 participants; CCNE1 amplification threshold definition (CCNE1 amplification >7 by specified NGS criteria) and ORR primary endpoint were specified; results were posted (first posted 2023-09-13) (NCT03253679 chunk 1).
- Azenosertib Cyclin E1 IHCâselected trial design: DENALI/GOG-3066 (NCT05128825) planned enrollment 170; Part 2 requires Cyclin E1-positive by central IHC and uses ORR per RECIST v1.1 as primary endpoint (NCT05128825 chunk 1).
- BLU-222 first-in-human trial design: VELA (NCT05252416) enrollment listed as 50; includes a cohort for platinum-resistant/refractory ovarian cancer with CCNE1 amplification; trial marked terminated before Phase 2 for reasons not due to safety (NCT05252416 chunk 1).
Cropped figure/table panels from Kim et al. (2025) show representative azenosertib clinical response cases and biomarker context (Cyclin E1 IHC and CCNE1 copy number), supporting the reported â57/â42/â30% tumor reductions (kim2025cycline1cdk2activation media 5f32e8dd, kim2025cycline1cdk2activation media cd829d1a, kim2025cycline1cdk2activation media 43760d10).
CCNE1 (cyclin E1; UniProt P24864) is best annotated as a CDK2-activating cyclin that enforces late-G1 progression and G1/S commitment via the RBâE2F axis, with activity and abundance tuned by SCFâFBXW7 phosphodegron-dependent ubiquitin-mediated degradation. In cancer, CCNE1 amplification/overexpression is a frequent genomic state (e.g., ~22% in TCGA ovarian cohort) associated with dysregulated cell-cycle entry and replication stress, creating translational vulnerabilities to checkpoint and cell-cycle therapeutics (WEE1 inhibitors, emerging CDK2 inhibitors, and CDK2/cyclin E degraders) increasingly implemented via NGS-based amplification calls and/or Cyclin E1 IHC selection (lashen2024theclinicopathologicalsignificance pages 1-2, boretto2024epidermalgrowthfactor pages 2-3, lashen2024theclinicopathologicalsignificance pages 9-11, kim2025cycline1cdk2activation pages 12-13).
References
(zhang2025anallostericcyclin pages 1-3): Yuanjin Zhang, Zhonglin Liu, Marscha Hirschi, Oleg Brodsky, Eric Johnson, Sang Joon Won, Asako Nagata, Divya Bezwada, Matthew D. Petroski, Jaimeen D. Majmudar, Sherry Niessen, Todd VanArsdale, Adam M. Gilbert, Matthew M. Hayward, Al E. Stewart, Andrew R. Nager, Bruno Melillo, and Benjamin F. Cravatt. An allosteric cyclin e-cdk2 site mapped by paralog hopping with covalent probes. Nature chemical biology, 21:420-431, Sep 2025. URL: https://doi.org/10.1038/s41589-024-01738-7, doi:10.1038/s41589-024-01738-7. This article has 13 citations and is from a highest quality peer-reviewed journal.
(kasirzadeh2024targetingcdk2to pages 2-3): Sara Kasirzadeh, Jimma Likisa Lenjisa, and Shudong Wang. Targeting cdk2 to combat drug resistance in cancer therapy. Future oncology, 20:1-17, Oct 2024. URL: https://doi.org/10.1080/14796694.2024.2416382, doi:10.1080/14796694.2024.2416382. This article has 13 citations and is from a peer-reviewed journal.
(lashen2024theclinicopathologicalsignificance pages 1-2): Ayat Lashen, Mashael Algethami, Shatha Alqahtani, Ahmed Shoqafi, Amera Sheha, Jennie N. Jeyapalan, Nigel P. Mongan, Emad A. Rakha, and Srinivasan Madhusudan. The clinicopathological significance of the cyclin d1/e1âcyclin-dependent kinase (cdk2/4/6)âretinoblastoma (rb1/prb1) pathway in epithelial ovarian cancers. International Journal of Molecular Sciences, 25:4060, Apr 2024. URL: https://doi.org/10.3390/ijms25074060, doi:10.3390/ijms25074060. This article has 12 citations.
(kim2025cycline1cdk2activation pages 13-14): Daehwan Kim, Heekyung Chung, Wen Liu, Kangjin Jeong, Tugba Y. Ozmen, Furkan Ozmen, Matthew J. Rames, Sangyub Kim, Xiao Guo, Nathan Jameson, Petrus R. de Jong, Steven Yea, Laurie Harford, Jiali Li, Cara A. Mathews, Deborah B. Doroshow, Vincent J. Charles, Doris Kim, Kimberlee Fischer, Ahmed A. Samatar, Adrian Jubb, Kevin D. Bunker, Kimberly Blackwell, Fiona Simpkins, Funda Meric-Bernstam, Gordon B. Mills, Olivier Harismendy, Jianhui Ma, and Mark R. Lackner. Cyclin e1/cdk2 activation defines a key vulnerability to wee1 kinase inhibition in gynecological cancers. NPJ Precision Oncology, Jan 2025. URL: https://doi.org/10.1038/s41698-024-00787-4, doi:10.1038/s41698-024-00787-4. This article has 17 citations and is from a peer-reviewed journal.
(kim2025cycline1cdk2activation pages 12-13): Daehwan Kim, Heekyung Chung, Wen Liu, Kangjin Jeong, Tugba Y. Ozmen, Furkan Ozmen, Matthew J. Rames, Sangyub Kim, Xiao Guo, Nathan Jameson, Petrus R. de Jong, Steven Yea, Laurie Harford, Jiali Li, Cara A. Mathews, Deborah B. Doroshow, Vincent J. Charles, Doris Kim, Kimberlee Fischer, Ahmed A. Samatar, Adrian Jubb, Kevin D. Bunker, Kimberly Blackwell, Fiona Simpkins, Funda Meric-Bernstam, Gordon B. Mills, Olivier Harismendy, Jianhui Ma, and Mark R. Lackner. Cyclin e1/cdk2 activation defines a key vulnerability to wee1 kinase inhibition in gynecological cancers. NPJ Precision Oncology, Jan 2025. URL: https://doi.org/10.1038/s41698-024-00787-4, doi:10.1038/s41698-024-00787-4. This article has 17 citations and is from a peer-reviewed journal.
(lashen2024theclinicopathologicalsignificance pages 7-9): Ayat Lashen, Mashael Algethami, Shatha Alqahtani, Ahmed Shoqafi, Amera Sheha, Jennie N. Jeyapalan, Nigel P. Mongan, Emad A. Rakha, and Srinivasan Madhusudan. The clinicopathological significance of the cyclin d1/e1âcyclin-dependent kinase (cdk2/4/6)âretinoblastoma (rb1/prb1) pathway in epithelial ovarian cancers. International Journal of Molecular Sciences, 25:4060, Apr 2024. URL: https://doi.org/10.3390/ijms25074060, doi:10.3390/ijms25074060. This article has 12 citations.
(lashen2024theclinicopathologicalsignificance pages 11-12): Ayat Lashen, Mashael Algethami, Shatha Alqahtani, Ahmed Shoqafi, Amera Sheha, Jennie N. Jeyapalan, Nigel P. Mongan, Emad A. Rakha, and Srinivasan Madhusudan. The clinicopathological significance of the cyclin d1/e1âcyclin-dependent kinase (cdk2/4/6)âretinoblastoma (rb1/prb1) pathway in epithelial ovarian cancers. International Journal of Molecular Sciences, 25:4060, Apr 2024. URL: https://doi.org/10.3390/ijms25074060, doi:10.3390/ijms25074060. This article has 12 citations.
(chen2025targetingcdk2and pages 1-3): Mei-Kuang Chen, Linjie Luo, Nicole Massoumi, and Khandan Keyomarsi. Targeting cdk2 and other novel cell cycle targets for breast cancer therapy. Jul 2025. URL: https://doi.org/10.1080/14728222.2025.2537412, doi:10.1080/14728222.2025.2537412. This article has 3 citations and is from a peer-reviewed journal.
(boretto2024epidermalgrowthfactor pages 1-2): Matteo Boretto, Maarten H. Geurts, Shashank Gandhi, Ziliang Ma, Nadzeya Staliarova, Martina Celotti, Sangho Lim, Gui-Wei He, Rosemary Millen, Else Driehuis, Harry Begthel, Lidwien Smabers, Jeanine Roodhart, Johan van Es, Wei Wu, and Hans Clevers. Epidermal growth factor receptor (egfr) is a target of the tumor-suppressor e3 ligase fbxw7. Proceedings of the National Academy of Sciences of the United States of America, Mar 2024. URL: https://doi.org/10.1073/pnas.2309902121, doi:10.1073/pnas.2309902121. This article has 26 citations and is from a highest quality peer-reviewed journal.
(boretto2024epidermalgrowthfactor pages 2-3): Matteo Boretto, Maarten H. Geurts, Shashank Gandhi, Ziliang Ma, Nadzeya Staliarova, Martina Celotti, Sangho Lim, Gui-Wei He, Rosemary Millen, Else Driehuis, Harry Begthel, Lidwien Smabers, Jeanine Roodhart, Johan van Es, Wei Wu, and Hans Clevers. Epidermal growth factor receptor (egfr) is a target of the tumor-suppressor e3 ligase fbxw7. Proceedings of the National Academy of Sciences of the United States of America, Mar 2024. URL: https://doi.org/10.1073/pnas.2309902121, doi:10.1073/pnas.2309902121. This article has 26 citations and is from a highest quality peer-reviewed journal.
(baxter2024cancerâassociatedfbxw7loss pages 15-16): Joseph S. Baxter, Rachel Brough, Dragomir B. Krastev, Feifei Song, Sandhya Sridhar, Aditi Gulati, John Alexander, Theodoros I. Roumeliotis, Zuza Kozik, Jyoti S. Choudhary, Syed Haider, Stephen J. Pettitt, Andrew N. J. Tutt, and Christopher J. Lord. Cancerâassociated fbxw7 loss is synthetic lethal with pharmacological targeting of cdc7. Molecular Oncology, 18:369-385, Oct 2024. URL: https://doi.org/10.1002/1878-0261.13537, doi:10.1002/1878-0261.13537. This article has 6 citations and is from a peer-reviewed journal.
(lashen2024theclinicopathologicalsignificance pages 9-11): Ayat Lashen, Mashael Algethami, Shatha Alqahtani, Ahmed Shoqafi, Amera Sheha, Jennie N. Jeyapalan, Nigel P. Mongan, Emad A. Rakha, and Srinivasan Madhusudan. The clinicopathological significance of the cyclin d1/e1âcyclin-dependent kinase (cdk2/4/6)âretinoblastoma (rb1/prb1) pathway in epithelial ovarian cancers. International Journal of Molecular Sciences, 25:4060, Apr 2024. URL: https://doi.org/10.3390/ijms25074060, doi:10.3390/ijms25074060. This article has 12 citations.
(kasirzadeh2024targetingcdk2to pages 1-2): Sara Kasirzadeh, Jimma Likisa Lenjisa, and Shudong Wang. Targeting cdk2 to combat drug resistance in cancer therapy. Future oncology, 20:1-17, Oct 2024. URL: https://doi.org/10.1080/14796694.2024.2416382, doi:10.1080/14796694.2024.2416382. This article has 13 citations and is from a peer-reviewed journal.
(house2025profilingtheactivity pages 12-12): Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, and Kerrie L. Faia. Profiling the activity of the potent and highly selective cdk2 inhibitor blu-222 reveals determinants of response in ccne1 -aberrant ovarian and endometrial tumors. Cancer Research, 85:1297-1309, Feb 2025. URL: https://doi.org/10.1158/0008-5472.can-24-2360, doi:10.1158/0008-5472.can-24-2360. This article has 17 citations and is from a highest quality peer-reviewed journal.
(kwiatkowski2025cdk2heterobifunctionaldegraders pages 1-1): Nicholas Kwiatkowski, Tong Liang, Zhe Sha, Philip N. Collier, Annan Yang, Murugappan Sathappa, Atanu Paul, Lijing Su, Xiaozhang Zheng, Robert Aversa, Kunhua Li, Revonda Mehovic, Christina Kolodzy, Susanne B. Breitkopf, Dapeng Chen, Charles L. Howarth, Karen Yuan, Hakryul Jo, Joseph D. Growney, Matthew Weiss, and Juliet Williams. Cdk2 heterobifunctional degraders co-degrade cdk2 and cyclin e resulting in efficacy in ccne1-amplified and overexpressed cancers. Cell chemical biology, 32 4:556-569.e24, Apr 2025. URL: https://doi.org/10.1016/j.chembiol.2025.03.006, doi:10.1016/j.chembiol.2025.03.006. This article has 9 citations and is from a domain leading peer-reviewed journal.
(NCT03253679 chunk 1): AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification. National Cancer Institute (NCI). 2019. ClinicalTrials.gov Identifier: NCT03253679
(NCT05128825 chunk 1): A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer. K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. 2022. ClinicalTrials.gov Identifier: NCT05128825
(NCT05252416 chunk 1): (VELA) Study of BLU-222 in Advanced Solid Tumors. Blueprint Medicines Corporation. 2022. ClinicalTrials.gov Identifier: NCT05252416
(kim2025cycline1cdk2activation media 5f32e8dd): Daehwan Kim, Heekyung Chung, Wen Liu, Kangjin Jeong, Tugba Y. Ozmen, Furkan Ozmen, Matthew J. Rames, Sangyub Kim, Xiao Guo, Nathan Jameson, Petrus R. de Jong, Steven Yea, Laurie Harford, Jiali Li, Cara A. Mathews, Deborah B. Doroshow, Vincent J. Charles, Doris Kim, Kimberlee Fischer, Ahmed A. Samatar, Adrian Jubb, Kevin D. Bunker, Kimberly Blackwell, Fiona Simpkins, Funda Meric-Bernstam, Gordon B. Mills, Olivier Harismendy, Jianhui Ma, and Mark R. Lackner. Cyclin e1/cdk2 activation defines a key vulnerability to wee1 kinase inhibition in gynecological cancers. NPJ Precision Oncology, Jan 2025. URL: https://doi.org/10.1038/s41698-024-00787-4, doi:10.1038/s41698-024-00787-4. This article has 17 citations and is from a peer-reviewed journal.
(kim2025cycline1cdk2activation media cd829d1a): Daehwan Kim, Heekyung Chung, Wen Liu, Kangjin Jeong, Tugba Y. Ozmen, Furkan Ozmen, Matthew J. Rames, Sangyub Kim, Xiao Guo, Nathan Jameson, Petrus R. de Jong, Steven Yea, Laurie Harford, Jiali Li, Cara A. Mathews, Deborah B. Doroshow, Vincent J. Charles, Doris Kim, Kimberlee Fischer, Ahmed A. Samatar, Adrian Jubb, Kevin D. Bunker, Kimberly Blackwell, Fiona Simpkins, Funda Meric-Bernstam, Gordon B. Mills, Olivier Harismendy, Jianhui Ma, and Mark R. Lackner. Cyclin e1/cdk2 activation defines a key vulnerability to wee1 kinase inhibition in gynecological cancers. NPJ Precision Oncology, Jan 2025. URL: https://doi.org/10.1038/s41698-024-00787-4, doi:10.1038/s41698-024-00787-4. This article has 17 citations and is from a peer-reviewed journal.
(kim2025cycline1cdk2activation media 43760d10): Daehwan Kim, Heekyung Chung, Wen Liu, Kangjin Jeong, Tugba Y. Ozmen, Furkan Ozmen, Matthew J. Rames, Sangyub Kim, Xiao Guo, Nathan Jameson, Petrus R. de Jong, Steven Yea, Laurie Harford, Jiali Li, Cara A. Mathews, Deborah B. Doroshow, Vincent J. Charles, Doris Kim, Kimberlee Fischer, Ahmed A. Samatar, Adrian Jubb, Kevin D. Bunker, Kimberly Blackwell, Fiona Simpkins, Funda Meric-Bernstam, Gordon B. Mills, Olivier Harismendy, Jianhui Ma, and Mark R. Lackner. Cyclin e1/cdk2 activation defines a key vulnerability to wee1 kinase inhibition in gynecological cancers. NPJ Precision Oncology, Jan 2025. URL: https://doi.org/10.1038/s41698-024-00787-4, doi:10.1038/s41698-024-00787-4. This article has 17 citations and is from a peer-reviewed journal.
id: P24864
gene_symbol: CCNE1
product_type: PROTEIN
status: IN_PROGRESS
taxon:
id: NCBITaxon:9606
label: Homo sapiens
description: >-
CCNE1 encodes cyclin E1, a regulatory subunit of the cyclin-dependent kinase CDK2.
Cyclin E1 binds and activates CDK2, driving phosphorylation of key substrates such
as RB1 to promote the G1/S transition of the cell cycle and commitment to S-phase
entry. Cyclin E1 itself has no catalytic activity; its role is to confer substrate
specificity and temporal activation on CDK2. The protein is predominantly nuclear
and its abundance is tightly regulated by SCF-FBXW7-dependent ubiquitin-mediated
proteolysis, triggered by phosphodegron motifs phosphorylated by CDK2 and GSK3.
CCNE1 amplification and overexpression are frequent in cancers, particularly
high-grade serous ovarian cancer (~22% of TCGA cases), where they drive replication
stress and genomic instability.
existing_annotations:
- term:
id: GO:0000082
label: G1/S transition of mitotic cell cycle
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
Core function. Cyclin E1 is the canonical regulator of G1/S transition via
CDK2 activation. Extensively supported by phylogenetic inference (IBA) and
all literature.
action: ACCEPT
reason: >-
G1/S transition is the defining biological process for cyclin E1. The deep
research (CCNE1-deep-research-falcon.md) confirms "Cyclin E1 is a non-enzymatic
regulatory subunit whose primary molecular function is to bind and activate
CDK2, thereby promoting late G1 progression and G1/S transition"
(kasirzadeh2024targetingcdk2to). IBA annotations for such core functions
are typically well-reviewed.
supported_by:
- reference_id: PMID:15838514
supporting_text: >-
Cyclin E-Cdk2 has long been considered an essential and master regulator of
progression through G1 phase of the cell cycle
- term:
id: GO:0005634
label: nucleus
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
Cyclin E1 is a nuclear protein as established by multiple lines of evidence
including the UniProt record which states "Nucleus" with experimental evidence
from PMID:7739542.
action: ACCEPT
reason: >-
Nuclear localization of cyclin E1 is well established. UniProt states
"SUBCELLULAR LOCATION: Nucleus" with experimental evidence. IBA annotation
is consistent.
supported_by:
- reference_id: PMID:19942931
supporting_text: >-
Mtd expression in proliferating cells colocalized with cyclin E1, a G(1)/S
phase cell cycle regulator
- term:
id: GO:0005737
label: cytoplasm
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
Cyclin E1 is also found in the cytoplasm. IHC studies show both nuclear and
cytoplasmic localization, and the deep research notes nucleocytoplasmic
shuttling.
action: ACCEPT
reason: >-
Cytoplasmic localization is supported by IHC evidence showing "cytoplasmic
cyclin E1 was frequently high (70% high vs 30% low)" in ovarian cancer
(lashen2024theclinicopathologicalsignificance). Cyclin E and CDK2 are
known to shuttle between nucleus and cytoplasm
(chen2025targetingcdk2and). IBA annotation is consistent.
- term:
id: GO:0016538
label: cyclin-dependent protein serine/threonine kinase regulator activity
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
Core molecular function of cyclin E1. It is a non-enzymatic regulatory subunit
that binds and activates CDK2, a cyclin-dependent serine/threonine kinase.
action: ACCEPT
reason: >-
This is the defining molecular function of cyclin E1. It does not have kinase
activity itself but activates CDK2. PMID:8207080 confirms "Cyclin E is a
regulatory subunit of the cdc2-related protein kinase cdk2." The IBA
annotation is at the right level of specificity.
supported_by:
- reference_id: PMID:8207080
supporting_text: >-
Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2,
which is activated shortly before S-phase entry, thus defining it as a G1
cyclin
- term:
id: GO:0097134
label: cyclin E1-CDK2 complex
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
Cyclin E1 is a defining component of the cyclin E1-CDK2 complex. Crystal
structure of the complex has been solved (PDB:1W98, PMID:15660127).
action: ACCEPT
reason: >-
UniProt states "Interacts with CDK2 protein kinase to form a serine/threonine
kinase holoenzyme complex." Multiple crystal structures confirm this
(PDB:1W98). ComplexPortal entry CPX-2015 explicitly defines the
Cyclin E1-CDK2 complex.
- term:
id: GO:0005815
label: microtubule organizing center
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
Cyclin E-CDK2 is known to play a role in centrosome duplication, and
localization to centrosomes (microtubule organizing centers) has been reported
in the literature for cyclin E in model organisms. The IBA annotation reflects
phylogenetic inference from orthologs.
action: ACCEPT
reason: >-
Cyclin E-CDK2 activity is required for centrosome duplication, and cyclin E
has been shown to localize to centrosomes. This is supported by the broader
cell cycle biology literature and is phylogenetically conserved (IBA).
- term:
id: GO:1900087
label: positive regulation of G1/S transition of mitotic cell cycle
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
Cyclin E1 positively regulates G1/S transition by activating CDK2, which
phosphorylates RB1 to release E2F transcription factors for S-phase gene
expression.
action: ACCEPT
reason: >-
This is a core function. The deep research confirms "CDK2-cyclin E activity
promotes S-phase entry in large part by phosphorylating RB, enabling E2F
transcriptional activation" (kasirzadeh2024targetingcdk2to). The IBA
annotation is at the right level of specificity.
supported_by:
- reference_id: PMID:15838514
supporting_text: >-
Cyclin E-Cdk2 has long been considered an essential and master regulator of
progression through G1 phase of the cell cycle
- term:
id: GO:0005634
label: nucleus
evidence_type: IEA
original_reference_id: GO_REF:0000120
review:
summary: >-
IEA annotation for nuclear localization, consistent with the IBA and IDA
annotations for the same term.
action: ACCEPT
reason: >-
Redundant with IBA and IDA annotations but not wrong. Nuclear localization
is well established for cyclin E1.
- term:
id: GO:0051301
label: cell division
evidence_type: IEA
original_reference_id: GO_REF:0000043
review:
summary: >-
IEA annotation from UniProt keyword mapping. Cell division is a broad term
that encompasses the G1/S transition role of cyclin E1.
action: ACCEPT
reason: >-
While broader than the more specific G1/S transition annotations, this IEA
is not wrong. Cyclin E1 is clearly involved in cell division. The UniProt
record includes "Cell cycle; Cell division" as keywords.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:10330164
review:
summary: >-
Interaction with p300 coactivator. PMID:10330164 shows cyclin E-Cdk2 binds
to the COOH-terminal region of p300, though this is described as a complex
interaction (cyclin E-Cdk2 rather than cyclin E alone).
action: MARK_AS_OVER_ANNOTATED
reason: >-
The term "protein binding" is uninformative. The actual finding is a specific
interaction of cyclin E-Cdk2 complex with the p300 coactivator. However,
the GO guidelines discourage generic protein binding annotations.
supported_by:
- reference_id: PMID:10330164
supporting_text: >-
the COOH-terminal region of p300 binds to cyclin E-cyclin-dependent kinase 2
(cyclin E-Cdk2) and TFIIB
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:11533444
review:
summary: >-
Interaction with FBXW7 (SCFFbw7) for phosphorylation-dependent ubiquitination.
This is a well-characterized substrate-E3 ligase interaction.
action: MARK_AS_OVER_ANNOTATED
reason: >-
The term "protein binding" is uninformative. The actual interaction is between
cyclin E and FBXW7 as part of SCF-mediated ubiquitination. This is better
captured by other annotations related to cyclin E degradation.
supported_by:
- reference_id: PMID:11533444
supporting_text: >-
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin
ligase
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:16223725
review:
summary: >-
Interaction with PIN1 prolyl isomerase. PIN1 regulates cyclin E stability.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. The actual finding is PIN1
regulation of cyclin E stability.
supported_by:
- reference_id: PMID:16223725
supporting_text: >-
The loss of PIN1 deregulates cyclin E and sensitizes mouse embryo fibroblasts
to genomic instability
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:16431923
review:
summary: >-
Interaction with SARS-CoV nucleocapsid protein, which inhibits cyclin-CDK
activity. This is a viral pathogen interaction, not a core function.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. The interaction is with a viral
protein (SARS-CoV nucleocapsid) and represents pathogen interference with
cell cycle, not a core function of cyclin E1.
supported_by:
- reference_id: PMID:16431923
supporting_text: >-
The nucleocapsid protein of severe acute respiratory syndrome-coronavirus
inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks
S phase progression in mammalian cells
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:16504183
review:
summary: >-
Interaction with FOXM1c transcription factor, regulated by Cyclin E/CDK2.
UniProt lists FOXM1 as an interaction partner.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. The actual finding is regulation
of FOXM1c by cyclin E/CDK2 complex phosphorylation.
supported_by:
- reference_id: PMID:16504183
supporting_text: >-
Regulation of the transcription factor FOXM1c by Cyclin E/CDK2
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:16721056
review:
summary: >-
Interaction with AKAP95 (A-kinase anchoring protein). G1/S cyclins interact
with PKA regulatory subunit via AKAP95.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. UniProt lists AKAP8 as an
interaction partner.
supported_by:
- reference_id: PMID:16721056
supporting_text: >-
G1/S Cyclins interact with regulatory subunit of PKA via A-kinase anchoring
protein, AKAP95
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:16765349
review:
summary: >-
Interaction with p21 (CDKN1A) in retinoid-induced apoptosis. p21 is a
well-known CDK inhibitor that forms complexes with cyclin E/CDK2.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. The cyclin E-CDK2-p21 interaction
is a core regulatory mechanism but should be annotated more specifically.
UniProt lists CDKN1A with 11 experiments.
supported_by:
- reference_id: PMID:16765349
supporting_text: >-
Increased p21 expression and complex formation with cyclin E/CDK2 in
retinoid-induced pre-B lymphoma cell apoptosis
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:17254966
review:
summary: >-
Interaction with p27Kip1 (CDKN1B). This is a key CDK inhibitor that
regulates cyclin E-CDK2 activity.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. The cyclin E-CDK2-p27 interaction
is well characterized. UniProt lists CDKN1B with 12 experiments.
supported_by:
- reference_id: PMID:17254966
supporting_text: >-
Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by
oncogenic tyrosine kinases
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:17254967
review:
summary: >-
Another study on p27-cyclin E-Cdk2 interaction, showing Src-dependent
phosphorylation of p27 regulates inhibition of cyclin E-Cdk2.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. This is the same well-characterized
p27-cyclin E-CDK2 interaction.
supported_by:
- reference_id: PMID:17254967
supporting_text: >-
p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:17525332
review:
summary: >-
Large-scale ATM/ATR substrate analysis. This is a high-throughput study
identifying proteins in DNA damage response networks, not a focused study
on cyclin E function.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding from a high-throughput study. Does not provide
specific information about cyclin E1 function.
supported_by:
- reference_id: PMID:17525332
supporting_text: >-
ATM and ATR substrate analysis reveals extensive protein networks responsive
to DNA damage
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:19470470
review:
summary: >-
Study on RSK1-p27Kip1 phosphorylation. Cyclin E is mentioned as a binding
partner of p27 but the study focuses on RSK1 function.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. The study focuses on RSK1
regulation of p27, with cyclin E as a known interactor.
supported_by:
- reference_id: PMID:19470470
supporting_text: >-
RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and
increase cell motility
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:21092281
review:
summary: >-
HTLV-I p30 decreases cyclin E-CDK2 interactions. This is a viral
interference study.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. This describes viral pathogen
interference with cyclin E-CDK2, not a core function.
supported_by:
- reference_id: PMID:21092281
supporting_text: >-
HTLV-I p30 inhibits multiple S phase entry checkpoints, decreases cyclin
E-CDK2 interactions and delays cell cycle progression
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:21952639
review:
summary: >-
Interaction with UHRF2 (NIRF), which ubiquitinates cyclin E1. UniProt
confirms this interaction with 4 experiments.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. The actual interaction is a
substrate-E3 ligase relationship where UHRF2 ubiquitinates cyclin E1.
UniProt states "Interacts directly with UHRF2; the interaction ubiquitinates
CCNE1."
supported_by:
- reference_id: PMID:21952639
supporting_text: >-
the ubiquitin ligase NIRF (also known as UHRF2), which induces G1 arrest,
interacts with multiple cell cycle proteins including cyclins (A2, B1, D1
and E1), p53 and pRB, and ubiquitinates cyclins D1 and E1
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:21988832
review:
summary: >-
High-throughput protein interaction study of the human liver. Not a focused
study on cyclin E1 function.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding from a large-scale interactome study. Uninformative
for cyclin E1 functional annotation.
supported_by:
- reference_id: PMID:21988832
supporting_text: >-
Toward an understanding of the protein interaction network of the human liver
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:23455922
review:
summary: >-
Large-scale AP-MS reproducibility study. Not a focused study on cyclin E1.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding from a high-throughput methods study. Uninformative
for cyclin E1 functional annotation.
supported_by:
- reference_id: PMID:23455922
supporting_text: >-
Interlaboratory reproducibility of large-scale human protein-complex analysis
by standardized AP-MS
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:23602568
review:
summary: >-
CMGC kinase group interactome study. CDK2 is a CMGC kinase, so cyclin E1
would be identified as an interactor.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding from a kinase interactome study. The cyclin E-CDK2
interaction is already well captured by more specific annotations.
supported_by:
- reference_id: PMID:23602568
supporting_text: >-
The protein interaction landscape of the human CMGC kinase group
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:23853094
review:
summary: >-
Foxp3 stability regulation by CDK2. The study shows CDK2 phosphorylates
Foxp3, with cyclin E as the activating partner.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. The actual biology is CDK2
phosphorylation of Foxp3, where cyclin E1 is the activating cyclin partner.
supported_by:
- reference_id: PMID:23853094
supporting_text: >-
Foxp3 protein stability is regulated by cyclin-dependent kinase 2
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:24358021
review:
summary: >-
SCML2 binding to CDK/CYCLIN/p21 complexes. Cyclin E is one of the cyclins
in such complexes.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. The study describes SCML2
modulating CDK/cyclin/p21 complexes, with cyclin E as one component.
supported_by:
- reference_id: PMID:24358021
supporting_text: >-
Polycomb protein SCML2 regulates the cell cycle by binding and modulating
CDK/CYCLIN/p21 complexes
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:25241761
review:
summary: >-
In situ proximity ligation assay (PLA) study for profiling endogenous
protein-protein interactions.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding from a methods-focused study. Uninformative for
cyclin E1 functional annotation.
supported_by:
- reference_id: PMID:25241761
supporting_text: >-
Using an in situ proximity ligation assay to systematically profile
endogenous protein-protein interactions in a pathway network
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:25852190
review:
summary: >-
Kinase network analysis in TRAIL-induced apoptosis. High-throughput study.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding from a high-throughput network analysis study.
Uninformative for cyclin E1 functional annotation.
supported_by:
- reference_id: PMID:25852190
supporting_text: >-
Integrative analysis of kinase networks in TRAIL-induced apoptosis provides
a source of potential targets for combination therapy
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:28514442
review:
summary: >-
Large-scale human interactome architecture study.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding from a large-scale interactome study. Uninformative
for cyclin E1 functional annotation.
supported_by:
- reference_id: PMID:28514442
supporting_text: >-
Architecture of the human interactome defines protein communities and disease
networks
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:32296183
review:
summary: >-
Binary protein interactome reference map.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding from a large-scale interactome mapping study.
Uninformative for cyclin E1 functional annotation.
supported_by:
- reference_id: PMID:32296183
supporting_text: >-
A reference map of the human binary protein interactome
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:33961781
review:
summary: >-
Dual proteome-scale interactome study showing cell-specific remodeling.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding from a large-scale interactome study. Uninformative
for cyclin E1 functional annotation.
supported_by:
- reference_id: PMID:33961781
supporting_text: >-
Dual proteome-scale networks reveal cell-specific remodeling of the human
interactome
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:34591612
review:
summary: >-
Protein interaction landscape of breast cancer.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding from a tissue-specific interactome study.
Uninformative for cyclin E1 functional annotation.
supported_by:
- reference_id: PMID:34591612
supporting_text: >-
A protein interaction landscape of breast cancer
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:35271311
review:
summary: >-
OpenCell endogenous tagging and cartography study.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding from a large-scale cellular organization study.
Uninformative for cyclin E1 functional annotation.
supported_by:
- reference_id: PMID:35271311
supporting_text: >-
OpenCell: Endogenous tagging for the cartography of human cellular
organization
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:35512704
review:
summary: >-
Mutation-directed neo-protein-protein interactions in cancer.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding from a high-throughput cancer study. Uninformative
for cyclin E1 functional annotation.
supported_by:
- reference_id: PMID:35512704
supporting_text: >-
Systematic discovery of mutation-directed neo-protein-protein interactions
in cancer
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:40205054
review:
summary: >-
Multimodal cell maps study.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding from a large-scale cellular mapping study.
Uninformative for cyclin E1 functional annotation.
supported_by:
- reference_id: PMID:40205054
supporting_text: >-
Multimodal cell maps as a foundation for structural and functional genomics
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:8553588
review:
summary: >-
HPV E7 oncoproteins bind cyclin E in a complex with CDK2 and p107. This
represents viral oncogene interaction with the cyclin E-CDK2 complex.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. The actual finding involves viral
E7 oncoprotein binding to cyclin E-CDK2-p107 complexes, which is a pathogen
interaction, not a core function.
supported_by:
- reference_id: PMID:8553588
supporting_text: >-
Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a
complex with cdk2 and p107
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:8756624
review:
summary: >-
Cyclin-binding motifs essential for p21CIP1 function. This demonstrates the
p21-cyclin E interaction is functionally important.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. The study reveals specific
cyclin-binding motifs in p21, but the annotation should be more specific
than "protein binding."
supported_by:
- reference_id: PMID:8756624
supporting_text: >-
Cyclin-binding motifs are essential for the function of p21CIP1
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:9840943
review:
summary: >-
Cyclin E2 discovery paper that also characterizes cyclin E1 interactions with
CDK2 and CDK3.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. The CDK2 interaction is already
captured by the more specific cyclin E1-CDK2 complex annotation
(GO:0097134).
supported_by:
- reference_id: PMID:9840943
supporting_text: >-
Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3,
is induced by viral oncoproteins
- term:
id: GO:0000307
label: cyclin-dependent protein kinase holoenzyme complex
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA annotation for CDK holoenzyme complex membership. This is a more general
parent of cyclin E1-CDK2 complex (GO:0097134).
action: ACCEPT
reason: >-
While more general than GO:0097134 (cyclin E1-CDK2 complex), this IEA
annotation is not wrong. Cyclin E1 is indeed a component of a
cyclin-dependent protein kinase holoenzyme complex (the CDK2 holoenzyme).
It is acceptable for IEA annotations to be broader.
- term:
id: GO:0016301
label: kinase activity
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA annotation attributing kinase activity to cyclin E1. However, cyclin E1
is NOT a kinase; it is a regulatory subunit that activates CDK2.
action: REMOVE
reason: >-
Cyclin E1 does not have kinase activity itself. It is a non-enzymatic
regulatory subunit that binds and activates CDK2. PMID:8207080 confirms
"Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2."
The kinase activity belongs to CDK2, not cyclin E1. The correct MF annotation
is GO:0016538 (cyclin-dependent protein serine/threonine kinase regulator
activity), which is already annotated. This IEA annotation is incorrect and
should be removed.
supported_by:
- reference_id: PMID:8207080
supporting_text: >-
Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2,
which is activated shortly before S-phase entry
- term:
id: GO:0016538
label: cyclin-dependent protein serine/threonine kinase regulator activity
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA annotation consistent with the IBA annotation for the same term.
This is the correct molecular function for cyclin E1.
action: ACCEPT
reason: >-
Consistent with the IBA annotation. This is the defining molecular function
of cyclin E1 as a CDK2 regulatory subunit.
- term:
id: GO:0019901
label: protein kinase binding
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA annotation for protein kinase binding. Cyclin E1 does bind CDK2 (a
protein kinase), so this is technically correct but vague.
action: ACCEPT
reason: >-
Cyclin E1 binds CDK2, which is a protein kinase. UniProt states "Interacts
with CDK2 protein kinase to form a serine/threonine kinase holoenzyme
complex" (PMID:15660127). While more informative terms exist (GO:0016538),
this IEA annotation is not incorrect and can be retained as a broader term.
- term:
id: GO:0097134
label: cyclin E1-CDK2 complex
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA annotation consistent with IBA annotation for the same term.
action: ACCEPT
reason: >-
Consistent with the IBA annotation. Cyclin E1 is a defining component of
the cyclin E1-CDK2 complex (ComplexPortal CPX-2015).
- term:
id: GO:0005654
label: nucleoplasm
evidence_type: IDA
original_reference_id: GO_REF:0000052
review:
summary: >-
IDA annotation from HPA immunofluorescence data showing nucleoplasmic
localization.
action: ACCEPT
reason: >-
Nucleoplasmic localization is consistent with cyclin E1 being a nuclear
protein that functions in cell cycle regulation within the nucleus.
This is supported by multiple lines of evidence.
- term:
id: GO:0000082
label: G1/S transition of mitotic cell cycle
evidence_type: NAS
original_reference_id: PMID:15838514
review:
summary: >-
NAS annotation from a review article on cyclin E in normal and neoplastic
cell cycles. Confirms the core function of cyclin E1 in G1/S transition.
action: ACCEPT
reason: >-
Core function annotation supported by review literature. PMID:15838514
states "Cyclin E-Cdk2 has long been considered an essential and master
regulator of progression through G1 phase of the cell cycle."
supported_by:
- reference_id: PMID:15838514
supporting_text: >-
Cyclin E-Cdk2 has long been considered an essential and master regulator of
progression through G1 phase of the cell cycle
- term:
id: GO:0000082
label: G1/S transition of mitotic cell cycle
evidence_type: IMP
original_reference_id: PMID:23083510
review:
summary: >-
IMP annotation from a study showing miR-16 targets cyclin E1 to inhibit
mesenchymal stem cell proliferation and induce cell cycle arrest. Cyclin E1
knockdown/downregulation caused cell cycle arrest, supporting its role in
G1/S transition.
action: ACCEPT
reason: >-
The study shows that miR-16 targets cyclin E1, and over-expression of
miR-16 "inhibited the proliferation and migration of decidua-derived
mesenchymal stem cells and induced cell-cycle arrest by targeting cyclin E1"
(PMID:23083510). This supports cyclin E1 involvement in G1/S transition.
supported_by:
- reference_id: PMID:23083510
supporting_text: >-
over-expressed miR-16 inhibited the proliferation and migration of
decidua-derived mesenchymal stem cells and induced cell-cycle arrest by
targeting cyclin E1
- term:
id: GO:1902462
label: positive regulation of mesenchymal stem cell proliferation
evidence_type: IMP
original_reference_id: PMID:23083510
review:
summary: >-
IMP annotation from miR-16 study in pre-eclampsia. While cyclin E1 promotes
proliferation of mesenchymal stem cells (shown by miR-16 targeting), this is
a very specific biological context (decidual MSCs in pre-eclampsia) rather
than a core function.
action: KEEP_AS_NON_CORE
reason: >-
Cyclin E1 does promote proliferation in MSCs as shown by the miR-16 study,
but this is a pleiotropic effect of its general cell cycle role in a
specific cell type context, not a core evolved function. The annotation is
technically supported but represents a context-specific manifestation.
supported_by:
- reference_id: PMID:23083510
supporting_text: >-
over-expressed miR-16 inhibited the proliferation and migration of
decidua-derived mesenchymal stem cells and induced cell-cycle arrest by
targeting cyclin E1
- term:
id: GO:0000082
label: G1/S transition of mitotic cell cycle
evidence_type: IMP
original_reference_id: PMID:25732226
review:
summary: >-
IMP annotation from study showing miR-30c-2-3p targets CCNE1 in breast
cancer cells. Inhibition of CCNE1 phenocopied effects on cell proliferation.
action: ACCEPT
reason: >-
The study confirms that CCNE1 downregulation affects cell cycle progression.
"inhibition of CCNE1 phenocopied the effects on cell proliferation"
(PMID:25732226). Supports G1/S transition role.
supported_by:
- reference_id: PMID:25732226
supporting_text: >-
inhibition of CCNE1 phenocopied the effects on cell proliferation
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:21540187
review:
summary: >-
Interaction with INCA1 (inhibitor of CDK interacting with cyclin A1).
UniProt confirms "Interacts with INCA1" (PMID:21540187).
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. The actual interaction is between
cyclin E1 and INCA1, a CDK inhibitor. UniProt confirms this interaction.
supported_by:
- reference_id: PMID:21540187
supporting_text: >-
we identified INCA1 as an interaction partner and a substrate of cyclin A1
in complex with CDK2
- term:
id: GO:0005634
label: nucleus
evidence_type: IDA
original_reference_id: PMID:19942931
review:
summary: >-
Nuclear localization of cyclin E1 observed in trophoblast cells. The study
shows Mtd-L colocalizes with cyclin E1 in the nuclear compartment.
action: ACCEPT
reason: >-
Nuclear localization confirmed by immunofluorescence in proliferating
trophoblast cells. "Mtd expression in proliferating cells colocalized with
cyclin E1, a G(1)/S phase cell cycle regulator" (PMID:19942931). Consistent
with UniProt annotation.
supported_by:
- reference_id: PMID:19942931
supporting_text: >-
Mtd expression in proliferating cells colocalized with cyclin E1, a G(1)/S
phase cell cycle regulator
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:17434132
review:
summary: >-
Structural study of Fbw7-Skp1-cyclin E complex. Demonstrates the molecular
basis for cyclin E recognition by SCF-FBXW7 for ubiquitin-mediated
degradation. This is a well-characterized interaction.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. The actual finding is the structural
basis for FBXW7 recognition of phosphorylated cyclin E degrons. This
interaction is critical for cyclin E turnover but "protein binding" does not
capture the functional significance.
supported_by:
- reference_id: PMID:17434132
supporting_text: >-
Cyclin E degradation is triggered by multisite phosphorylation, which
induces binding to the SCF(Fbw7) ubiquitin ligase complex
- term:
id: GO:0005654
label: nucleoplasm
evidence_type: TAS
original_reference_id: Reactome:R-HSA-187520
review:
summary: >-
Reactome TAS annotation for nucleoplasmic localization, from the Cyclin
E/A:Cdk2-mediated phosphorylation of p27/p21 reaction.
action: ACCEPT
reason: >-
Cyclin E-CDK2 mediates phosphorylation of p27/p21 in the nucleoplasm as
part of the Skp2-mediated degradation pathway. Consistent with nuclear
function.
- term:
id: GO:0005654
label: nucleoplasm
evidence_type: TAS
original_reference_id: Reactome:R-HSA-187552
review:
summary: >-
Reactome TAS annotation for nucleoplasm, from binding of phospho-p27/p21
to SCF(Skp2):Cks1 complex.
action: ACCEPT
reason: >-
Consistent with established nucleoplasmic function of cyclin E-CDK2 complex.
- term:
id: GO:0005654
label: nucleoplasm
evidence_type: TAS
original_reference_id: Reactome:R-HSA-187574
review:
summary: >-
Reactome TAS annotation for nucleoplasm, from degradation of ubiquitinated
p27/p21 by 26S proteasome.
action: ACCEPT
reason: >-
Consistent with nucleoplasmic localization during cell cycle regulation.
- term:
id: GO:0005654
label: nucleoplasm
evidence_type: TAS
original_reference_id: Reactome:R-HSA-187575
review:
summary: >-
Reactome TAS annotation for nucleoplasm, from ubiquitination of
phospho-p27/p21.
action: ACCEPT
reason: >-
Consistent with nucleoplasmic localization during cell cycle regulation.
- term:
id: GO:0005654
label: nucleoplasm
evidence_type: TAS
original_reference_id: Reactome:R-HSA-188350
review:
summary: >-
Reactome TAS annotation for nucleoplasm, from CAK-mediated phosphorylation
of Cyclin E:Cdk2.
action: ACCEPT
reason: >-
Consistent with nucleoplasmic localization during cell cycle regulation.
- term:
id: GO:0005654
label: nucleoplasm
evidence_type: TAS
original_reference_id: Reactome:R-HSA-188386
review:
summary: >-
Reactome TAS annotation for nucleoplasm, from association of Rb with
Cyclin E:Cdk2 complexes.
action: ACCEPT
reason: >-
Consistent with nucleoplasmic localization for RB1 phosphorylation by
cyclin E-CDK2.
- term:
id: GO:0005654
label: nucleoplasm
evidence_type: TAS
original_reference_id: Reactome:R-HSA-188390
review:
summary: >-
Reactome TAS annotation for nucleoplasm, from Cyclin E:CDK2-mediated
phosphorylation of RB1.
action: ACCEPT
reason: >-
Consistent with nucleoplasmic localization for the core function of
RB1 phosphorylation.
- term:
id: GO:0005654
label: nucleoplasm
evidence_type: TAS
original_reference_id: Reactome:R-HSA-69005
review:
summary: >-
Reactome TAS annotation for nucleoplasm, from Cdc6 phosphorylation by CDK.
action: ACCEPT
reason: >-
Consistent with nucleoplasmic localization. Cdc6 phosphorylation by
cyclin E-CDK2 is part of DNA replication licensing.
- term:
id: GO:0005654
label: nucleoplasm
evidence_type: TAS
original_reference_id: Reactome:R-HSA-69195
review:
summary: >-
Reactome TAS annotation for nucleoplasm, from phosphorylation of Cyclin
E:CDK2 complexes by WEE1.
action: ACCEPT
reason: >-
Consistent with nucleoplasmic localization during cell cycle checkpoint
regulation.
- term:
id: GO:0005654
label: nucleoplasm
evidence_type: TAS
original_reference_id: Reactome:R-HSA-69199
review:
summary: >-
Reactome TAS annotation for nucleoplasm, from dephosphorylation of Cyclin
E:Cdk2 complexes by Cdc25A.
action: ACCEPT
reason: >-
Consistent with nucleoplasmic localization during cell cycle regulation.
- term:
id: GO:0005829
label: cytosol
evidence_type: TAS
original_reference_id: Reactome:R-HSA-157906
review:
summary: >-
Reactome TAS annotation for cytosol, from translocation of Cyclin E:Cdk2
complex to the nucleus. Cyclin E-CDK2 is present in the cytosol before
nuclear translocation.
action: ACCEPT
reason: >-
Cyclin E-CDK2 complexes form in the cytosol before translocation to the
nucleus. The Reactome reaction R-HSA-157906 specifically describes this
translocation, implying cytosolic presence.
- term:
id: GO:0005829
label: cytosol
evidence_type: TAS
original_reference_id: Reactome:R-HSA-69191
review:
summary: >-
Reactome TAS annotation for cytosol, from formation of Cyclin E:Cdk2
complexes.
action: ACCEPT
reason: >-
Cyclin E-CDK2 complex formation occurs in the cytosol. Consistent with
known biology of cyclin-CDK complex assembly.
- term:
id: GO:0005829
label: cytosol
evidence_type: TAS
original_reference_id: Reactome:R-HSA-8961846
review:
summary: >-
Reactome TAS annotation for cytosol, from CCNE1 gene transcription
stimulated by E2F1. This annotation seems to be about the gene product
being present in cytosol in the context of its transcriptional regulation.
action: ACCEPT
reason: >-
While the Reactome reaction is about transcriptional regulation, cyclin E1
protein is synthesized in the cytosol. Consistent with cytoplasmic
localization evidence.
- term:
id: GO:0005829
label: cytosol
evidence_type: TAS
original_reference_id: Reactome:R-HSA-9706390
review:
summary: >-
Reactome TAS annotation for cytosol from RHOBTB3 interaction at trans-Golgi
network. This is a less well-characterized interaction.
action: ACCEPT
reason: >-
While the RHOBTB3 interaction context is less well characterized for cyclin
E1, cytosolic presence is consistent with known nucleocytoplasmic shuttling
of cyclin E.
- term:
id: GO:0006468
label: protein phosphorylation
evidence_type: IMP
original_reference_id: PMID:10500095
review:
summary: >-
PMID:10500095 describes Cullin-3 targeting cyclin E for ubiquitination. The
paper discusses cyclin E phosphorylation as a signal for degradation, and
cyclin E-CDK2 complex kinase activity, but cyclin E itself does not catalyze
phosphorylation. Cyclin E1 is a regulatory subunit, not a kinase.
action: MODIFY
reason: >-
Cyclin E1 does not catalyze protein phosphorylation itself. It is a
non-enzymatic regulatory subunit that activates CDK2. The annotation should
be modified to reflect that cyclin E1 regulates protein kinase activity
rather than directly performing phosphorylation. PMID:10500095 discusses
"cyclin E-Cdk2 complexes" where CDK2 is the catalytic subunit. The paper
actually focuses on "Cyclin E is an unstable protein that is degraded in a
ubiquitin- and proteasome-dependent pathway."
proposed_replacement_terms:
- id: GO:0045859
label: regulation of protein kinase activity
supported_by:
- reference_id: PMID:10500095
supporting_text: >-
Cyclin E is an unstable protein that is degraded in a ubiquitin- and
proteasome- dependent pathway
- term:
id: GO:0005634
label: nucleus
evidence_type: IDA
original_reference_id: PMID:16109376
review:
summary: >-
PMID:16109376 is about the bromodomain protein Brd4 and P-TEFb, not directly
about cyclin E1. Brd4 interacts with cyclinT1 and Cdk9. The reference
appears questionable for a CCNE1 nuclear localization annotation, as the
paper primarily concerns cyclinT1/Cdk9. However, nuclear localization of
cyclin E1 is well established by multiple other lines of evidence,
including UniProt annotation with PMID:7739542 and IDA from PMID:19942931.
action: ACCEPT
reason: >-
Although the specific reference PMID:16109376 may be a curatorial error
(the paper focuses on Brd4/P-TEFb/cyclinT1/Cdk9 rather than cyclin E1),
the nuclear localization of CCNE1 itself is unambiguously established.
UniProt states "SUBCELLULAR LOCATION: Nucleus" with experimental evidence,
and multiple other IDA annotations confirm nuclear localization
(PMID:19942931). The annotation conclusion is correct even if the cited
reference is questionable.
supported_by:
- reference_id: PMID:16109376
supporting_text: >-
Proteomic analysis revealed that Brd4 interacts with cyclinT1 and Cdk9 that
constitutes core positive transcription elongation factor b (P-TEFb)
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:9891079
review:
summary: >-
Interaction with BAF155 and BRG1, components of the SWI-SNF chromatin
remodeling complex. Cyclin E associates with these components and modulates
BRG1-induced growth arrest.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Generic protein binding is uninformative. The actual finding is a specific
interaction between cyclin E and SWI-SNF complex components (BAF155, BRG1)
that may modulate chromatin remodeling during cell cycle progression.
supported_by:
- reference_id: PMID:9891079
supporting_text: >-
BRG1 and BAF155, mammalian homologs of yeast SWI2 and SWI3, respectively,
are found in cyclin E complexes and are phosphorylated by cyclin
E-associated kinase activity
- term:
id: GO:0000082
label: G1/S transition of mitotic cell cycle
evidence_type: NAS
original_reference_id: PMID:8207080
review:
summary: >-
NAS annotation from the alternative splicing paper. The paper establishes
cyclin E as a G1 cyclin that activates CDK2 for S-phase entry.
action: ACCEPT
reason: >-
PMID:8207080 confirms "Cyclin E is a regulatory subunit of the cdc2-related
protein kinase cdk2, which is activated shortly before S-phase entry, thus
defining it as a G1 cyclin." Core function annotation.
supported_by:
- reference_id: PMID:8207080
supporting_text: >-
Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2,
which is activated shortly before S-phase entry, thus defining it as a G1
cyclin
core_functions:
- description: >-
Cyclin E1 functions as a regulatory subunit that binds and activates CDK2
(cyclin-dependent kinase 2), forming the cyclin E1-CDK2 holoenzyme complex.
The cyclin E1-CDK2 complex phosphorylates RB1, releasing E2F transcription
factors to activate S-phase gene expression, thereby driving the G1/S
transition of the mitotic cell cycle.
molecular_function:
id: GO:0016538
label: cyclin-dependent protein serine/threonine kinase regulator activity
directly_involved_in:
- id: GO:1900087
label: positive regulation of G1/S transition of mitotic cell cycle
locations:
- id: GO:0005654
label: nucleoplasm
in_complex:
id: GO:0097134
label: cyclin E1-CDK2 complex
supported_by:
- reference_id: PMID:15838514
supporting_text: >-
Cyclin E-Cdk2 has long been considered an essential and master regulator of
progression through G1 phase of the cell cycle
- reference_id: PMID:8207080
supporting_text: >-
Cyclin E is a regulatory subunit of the cdc2-related protein kinase cdk2,
which is activated shortly before S-phase entry, thus defining it as a G1
cyclin
references:
- id: GO_REF:0000033
title: Annotation inferences using phylogenetic trees
findings: []
- id: GO_REF:0000043
title: Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping
findings: []
- id: GO_REF:0000052
title: Gene Ontology annotation based on curation of immunofluorescence data
findings: []
- id: GO_REF:0000107
title: Automatic transfer of experimentally verified manual GO annotation data
to orthologs using Ensembl Compara
findings: []
- id: GO_REF:0000120
title: Combined Automated Annotation using Multiple IEA Methods
findings: []
- id: PMID:10330164
title: Specificity of cyclin E-Cdk2, TFIIB, and E1A interactions with a common
domain of the p300 coactivator.
findings: []
- id: PMID:10500095
title: Cullin-3 targets cyclin E for ubiquitination and controls S phase in
mammalian cells.
findings: []
- id: PMID:11533444
title: Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7
ubiquitin ligase.
findings: []
- id: PMID:15838514
title: Cyclin E in normal and neoplastic cell cycles.
findings: []
- id: PMID:16109376
title: The bromodomain protein Brd4 is a positive regulatory component of P-TEFb
and stimulates RNA polymerase II-dependent transcription.
findings: []
- id: PMID:16223725
title: The loss of PIN1 deregulates cyclin E and sensitizes mouse embryo
fibroblasts to genomic instability.
findings: []
- id: PMID:16431923
title: The nucleocapsid protein of severe acute respiratory
syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase
complex and blocks S phase progression in mammalian cells.
findings: []
- id: PMID:16504183
title: Regulation of the transcription factor FOXM1c by Cyclin E/CDK2.
findings: []
- id: PMID:16721056
title: G1/S Cyclins interact with regulatory subunit of PKA via A-kinase
anchoring protein, AKAP95.
findings: []
- id: PMID:16765349
title: Increased p21 expression and complex formation with cyclin E/CDK2 in
retinoid-induced pre-B lymphoma cell apoptosis.
findings: []
- id: PMID:17254966
title: Cdk-inhibitory activity and stability of p27Kip1 are directly regulated
by oncogenic tyrosine kinases.
findings: []
- id: PMID:17254967
title: p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2.
findings: []
- id: PMID:17434132
title: 'Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated
substrate recognition by SCF ubiquitin ligases.'
findings: []
- id: PMID:17525332
title: ATM and ATR substrate analysis reveals extensive protein networks
responsive to DNA damage.
findings: []
- id: PMID:19470470
title: RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition
and increase cell motility.
findings: []
- id: PMID:19942931
title: 'Mtd/Bok takes a swing: proapoptotic Mtd/Bok regulates trophoblast cell
proliferation during human placental development and in preeclampsia.'
findings: []
- id: PMID:21092281
title: HTLV-I p30 inhibits multiple S phase entry checkpoints, decreases cyclin
E-CDK2 interactions and delays cell cycle progression.
findings: []
- id: PMID:21540187
title: Inhibitor of cyclin-dependent kinase (CDK) interacting with cyclin A1
(INCA1) regulates proliferation and is repressed by oncogenic signaling.
findings: []
- id: PMID:21952639
title: NIRF constitutes a nodal point in the cell cycle network and is a
candidate tumor suppressor.
findings: []
- id: PMID:21988832
title: Toward an understanding of the protein interaction network of the human
liver.
findings: []
- id: PMID:23083510
title: miR-16 inhibits the proliferation and angiogenesis-regulating potential of
mesenchymal stem cells in severe pre-eclampsia.
findings: []
- id: PMID:23455922
title: Interlaboratory reproducibility of large-scale human protein-complex
analysis by standardized AP-MS.
findings: []
- id: PMID:23602568
title: The protein interaction landscape of the human CMGC kinase group.
findings: []
- id: PMID:23853094
title: Foxp3 protein stability is regulated by cyclin-dependent kinase 2.
findings: []
- id: PMID:24358021
title: Polycomb protein SCML2 regulates the cell cycle by binding and modulating
CDK/CYCLIN/p21 complexes.
findings: []
- id: PMID:25241761
title: Using an in situ proximity ligation assay to systematically profile
endogenous protein-protein interactions in a pathway network.
findings: []
- id: PMID:25732226
title: 'MicroRNA-30c-2-3p negatively regulates NF-ÎșB signaling and cell cycle
progression through downregulation of TRADD and CCNE1 in breast cancer.'
findings: []
- id: PMID:25852190
title: Integrative analysis of kinase networks in TRAIL-induced apoptosis
provides a source of potential targets for combination therapy.
findings: []
- id: PMID:28514442
title: Architecture of the human interactome defines protein communities and
disease networks.
findings: []
- id: PMID:32296183
title: A reference map of the human binary protein interactome.
findings: []
- id: PMID:33961781
title: Dual proteome-scale networks reveal cell-specific remodeling of the human
interactome.
findings: []
- id: PMID:34591612
title: A protein interaction landscape of breast cancer.
findings: []
- id: PMID:35271311
title: 'OpenCell: Endogenous tagging for the cartography of human cellular
organization.'
findings: []
- id: PMID:35512704
title: Systematic discovery of mutation-directed neo-protein-protein interactions
in cancer.
findings: []
- id: PMID:40205054
title: Multimodal cell maps as a foundation for structural and functional
genomics.
findings: []
- id: PMID:8207080
title: Alternative splicing of human cyclin E.
findings: []
- id: PMID:8553588
title: Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a
complex with cdk2 and p107.
findings: []
- id: PMID:8756624
title: Cyclin-binding motifs are essential for the function of p21CIP1.
findings: []
- id: PMID:9840943
title: Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and
CDK3, is induced by viral oncoproteins.
findings: []
- id: PMID:9891079
title: 'Cyclin E associates with BAF155 and BRG1, components of the mammalian
SWI-SNF complex, and alters the ability of BRG1 to induce growth arrest.'
findings: []
- id: Reactome:R-HSA-157906
title: Translocation of Cyclin E:Cdk2 complex to the nucleus
findings: []
- id: Reactome:R-HSA-187520
title: Cyclin E/A:Cdk2-mediated phosphorylation of p27/p21
findings: []
- id: Reactome:R-HSA-187552
title: Binding of phospho-p27/p21:Cdk2:Cyclin E/A to the SCF(Skp2):Cks1 complex
findings: []
- id: Reactome:R-HSA-187574
title: Degradation of ubiquitinated p27/p21 by the 26S proteasome
findings: []
- id: Reactome:R-HSA-187575
title: Ubiquitination of phospho-p27/p21
findings: []
- id: Reactome:R-HSA-188350
title: CAK-mediated phosphorylation of Cyclin E:Cdk2
findings: []
- id: Reactome:R-HSA-188386
title: Association of Rb with Cyclin E:Cdk2 complexes
findings: []
- id: Reactome:R-HSA-188390
title: Cyclin E:CDK2-mediated phosphorylation of RB1
findings: []
- id: Reactome:R-HSA-69005
title: Cdc6 protein is phosphorylated by CDK
findings: []
- id: Reactome:R-HSA-69191
title: Formation of Cyclin E:Cdk2 complexes
findings: []
- id: Reactome:R-HSA-69195
title: Phosphorylation of Cyclin E:CDK2 complexes by WEE1
findings: []
- id: Reactome:R-HSA-69199
title: Dephosphorylation of Cyclin E:Cdk2 complexes by Cdc25A
findings: []
- id: Reactome:R-HSA-8961846
title: CCNE1 gene transcription is stimulated by E2F1
findings: []
- id: Reactome:R-HSA-9706390
title: RHOBTB3 binds interacting proteins at trans-Golgi network
findings: []